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ABSTRACT 
Actinomycetes are widespread in marine ecosystem. They are of interest in 
research field as they are capable to produce bioactive secondary metabolites which can 
be developed into useful pharmaceutical products. An example of the product is 
antibiotics which can be used to treat infectious diseases. The potential of antibacterial 
and antifungal activity of eleven marine derived actinomycetes from the genus 
Streptomyces were studied. They were tested against bacteria Enterobacter faecalis, 
Staphylococcus aureus, Bacillus subtilis, Pleisiomonas shigelloides and Pseudomonas 
aeruginosa and fungi Candida parapsilosis and Candida albicans. Primary screening 
by the cross streak method and secondary screening by diffusion using paper disc 
method with crude extracts were carried out in this study. Media optimization was also 
carried out to optimize the media for production of bioactive secondary metabolites. Of 
the eleven strains studied, strain T53 exhibited the strongest antibacterial activity 
against E. faecalis. Gram-positive bacteria were more susceptible than Gram-negative 
bacteria. Strain T53, T52, T9 and T12 had broad spectrum activities. Strain T53, T16, 
T15 and T4 exhibited antifungal activity against all tested fungi. Yeast extract-malt 
extract agar (ISP2) and agitated fermentation were the best media and the best 
fermentation condition, respectively.  
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ABSTRAK  
Actinomycete boleh ditemui dengan banyak di dalam ekosistem marin. 
Organisma tersebut digunakan dalam bidang penyelidikan berdasarkan keupayaannya 
menghasilkan produk bioaktif sekunder. Produk tersebut boleh diproses untuk 
menghasilkan produk farmaseutikal. Antibiotik adalah antara produk farmaseutikal 
yang boleh dihasilkan untuk merawat jangkitan penyakit. Sebelas actinomycete 
daripada ekosistem marin yang telah dikenalpasti sebagai Streptomyces sp. telah dipilih 
untuk ujian aktiviti antibakteria dan antikulat. Aktiviti antibakteria dan antikulat telah di 
uji terhadap bakteria Enterobacter faecalis, Staphylococcus aureus, Bacillus subtilis, 
Pleisiomonas shigelloides dan Pseudomonas aeruginosa serta kulat/yis Candida 
parapsilosis dan Candida albicans. Kaedah ‘cross streak’ dan ‘paper disc’ telah 
diaplikasikan dalam ujian ini. Kaedah ‘paper disc’ turut diaplikasikan dalam ujian kedua 
untuk mengetahui media yang terbaik dalam penghasilan produk bioaktif sekunder. 
Daripada sebelas actinomycete yang dikaji, T53 mempamerkan aktiviti penyekatan 
pertumbuhan yang paling tinggi terhadap E. faecalis. Bakteria Gram-positif adalah lebih 
mudah disekat pertumbuhannya berbanding bakteria Gram-negatif. Aktinomycete T53, 
T52, T9 dan T12 menyekat pertumbuhan kedua-dua bakteria Gram-positif dan Gram-
negatif. Actinomycete T53, T16, T15 dan T4 menyekat pertumbuhan semua kulat/yis. 
Yis-malta ekstrak agar (ISP2) dan sistem fermentasi ‘agitation’ adalah media dan sistem 
fermentasi yang terbaik dalam penghasilan produk bioaktif sekunder.    
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1. INTRODUCTION  
 Healthcare-associated infections are problems that affect human life. The problems 
have been of concern in our community many years back until today. The infections are 
usually caused by pathogens which are bacteria and fungi. Pathogenic bacteria can be     
divided into two, Gram-positive bacteria and Gram-negative bacteria. These pathogenic 
bacteria can cause diseases in host organisms including human. Examples of Gram-positive 
pathogenic bacteria are Enterococcus faecalis, Staphylococcus aureus and Bacillus subtilis. 
Examples of Gram-negative pathogenic bacteria are Pleisiomonas shigelloides and 
Pseudomonas aeruginosa.    
 One of the comparative characteristic that differentiates Gram-positive bacteria 
from Gram-negative bacteria is their cell walls. Gram-positive bacteria have simpler walls, 
with a relatively large amount (multilayered) of peptidoglycan (Campbell et al., 1999) 
without lipid outer membrane. On the other hand, Gram-negative bacteria have complex 
wall but less peptidoglycan (single-layered). An outer membrane on the Gram-negative 
bacteria cell wall contains lipopolysaccharides which are carbohydrates bonded to lipids 
(Campbell et al., 1999). Another comparative characteristic is the difference in the Gram-
staining by Gram-staining method. Gram-positive bacteria retain the crystal violet dye and 
stain dark violet or purple. While Gram-negative bacteria can be decolorized to accept 
counterstain (safranin) and stain red.  
Gram-positive pathogenic bacteria as well as Gram-negative pathogenic bacteria 
can cause infections in human body. They are usually associated with cancer patients and 
nosocomial infections. The bacteria are either pathogens or opportunistic pathogens. The 
bacteria have also been reported to cause opportunistic infections of patients after 
operations in hospitals. Jones (1996) and Moellering (1998a) reported that the past two 
decades have seen a dramatic shift in the incidence of certain bacterial infections in both 
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the community and hospital settings. This shows that infections by pathogenic bacteria are 
increasing. With the increase in bacteria infection, human health will be affected. 
  Gram-positive pathogenic bacteria can be found in the gastrointestinal of human 
body as well as mucous membranes such as mouth, vagina and skin. Appelbaum and 
Jacobs (2005) reported that Gram-positive bacteria such as staphylococci and streptococci 
have historically been and still remain, major causes of human morbidity and mortality 
throughout the world. Other than that, there is a report that staphylococci are the most 
common pathogens in nosocomial meningitis (Palabiyikoglu, 2003) and these infections 
can cause serious clinical outcomes (Palabiyikoglu et al., 2006). Archer (1998) reported 
that in the last decade, the staphylococci have again emerged as the predominant organisms 
causing infections in the hospital setting. One example is S. aureus which can cause 
infections of the skin and other organs. The infections are common in people with frequent 
skin injury. It is seen most commonly in pre-pubertal children and certain occupational 
groups such as healthcare workers. The bacteria are able to invade via broken skin and 
mucous membranes.   
Other than the staphylococci, the enterococci are also among the most common 
pathogens. Moellering (1998a,b) reported that enterococci have also ascended in 
importance. Other researchers also reported that the Enterococcus spp. are now the third or 
fourth most common blood stream infection pathogen among hospitalized patients (Pfaller 
et al., 1998). Jones et al. (1999) reported that E. faecalis is the dominant species among 
hospitalized patients and the most prevalent (59.6%) and the most common cause of 
enterococcal infection. E. faecalis can cause endocarditis, as well as bladder, prostate and 
epididymal infections. The bacteria can cause life-threatening infections in humans 
especially in the nosocomial (hospital) environment.  
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On the other hand, B. subtilis is normally considered to be non-pathogenic. 
However, the bacteria has been linked to food borne illness causing diarrhea, nausea, 
vomiting, and associated with rice dishes served in oriental restaurants. B.subtilis can 
survive the extreme heating that is often used to cook food. The bacteria is also responsible 
for causing ropiness, a sticky and stringy consistency caused by bacterial production of 
long-chain polysaccharides in spoiled bread dough.  
 Gram-negative pathogenic bacteria can be found in the gastrointestinal tracts in the 
human body. The pathogenic bacteria such as P. aeruginosa have been reported to cause 
opportunistic infectious diseases in hospitals. The bacteria can cause nosocomial 
pneumonia, hospital-acquired urinary tract infections, surgical wound infections as well as 
bloodstream infections. The bacteria can also cause opportunistic infections in 
immunocompromised patients such as cancer and bone patients. P. aeruginosa can also 
cause chronic infections in cystic fibrosis patients. 
 Another example of Gram-negative pathogenic bacteria is P. shigelloides which is a 
common cause of gastrointestinal complications. The bacteria can also cause septicaemia 
and meningitis in patients with underlying disorders and as well as in immunocompromised 
patients.    
Besides pathogenic bacteria, fungi also cause infections and diseases in human. 
Fungi are normally present on the skin and also in mucous membranes such as the vagina, 
mouth or rectum. They can also travel through the blood stream and affect the throat, 
intestines and heart valves. Fungi including yeasts have also been reported to cause a high 
rate of infections in human body. Casadevall et al. (2002) stated that the prevalence of 
fungal diseases has increased markedly in hospitalized patients and other individuals with 
immune impairment. Kuti et al. (2002) reported that the fungal infections which constituted 
a problem exclusively relevant to dermatology can also cause mortality.  
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One example of human pathogenic fungi is yeast. Yeast is identified as a single-cell 
organism. Examples of yeasts are Candida albicans and Candida parapsilosis. Yeasts 
infections known as candidiasis are very common in human. Pfaller and Wenzel (1992) 
reported that Candida spp. became the third most common present isolates found in 
hemocultures in the USA. C. albicans is the most common cause of candidiasis. The 
pathogen is normally found in the lower bowel, vagina and skin. Another example of 
pathogenic fungi is C. parapsilosis which can cause major infection in intensive care units, 
premature infants and immunocompromised adults.  
The increase in the infections of pathogenic bacteria and fungi happens because of 
drug resistance among the pathogens. A number of pathogenic bacteria are multiple drugs 
resistant. The bacteria are reported to rapidly develop resistance to multiple classes of 
antimicrobial agents (Kwa et al., 2007). Resistance to antibiotics occurs typically as a result 
of drug inactivation/modification, target alteration and reduced accumulation owing to 
decreased permeability and/or increased efflux (Poole, 2002). 
Amyes and Thomson (1995) reported that some hospital-acquired pathogens are 
becoming totally resistant to antibiotics. Examples of those pathogens are E. faecalis, S. 
aureus and P. aeruginosa. Appelbaum and Jacobs (2005) reported that enterococci are 
largely of interest because of their increasing resistance to vancomycin. E. faecalis is 
resistant to many commonly used antimicrobial agents such as aminoglycosides, 
cephalosporins, oxacillin and vancomycin.  
Kitouni et al. (2005) reported that the vancomycin was the antibiotic of choice for 
the treatment of the infections caused by methicillin-resistant Staphylococcus aureus, until 
the appearance of the first resistance strains to vancomycin. While methicillin resistance in 
S. aureus (MRSA) has been reported to become common (Diekema et al., 2001) and has 
become a major problem in many countries (Palavecino, 2004). Woo et al. (2006) reported 
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that antibiotic resistant bacteria, such as penicillin resistant Streptococcus pneumoniae and 
vancomycin intermediate-resistant Staphylococcus aureus, are often multi-drug resistant, 
and thus produced numerous problems and obstacles on the clinical management of these 
infections. 
Jones (2001) and Landman et al. (2002) reported that the prevalence rates of 
multidrug resistance (MDR) among Gram-negative bacteria are on the rise. Other than that, 
the increase in the multidrug resistance of Gram-negative bacteria is reported to be high 
especially in intensive care units (Flournoy et al., 2000; Obstritch et al., 2004). P. 
aeruginosa is reported to be resistant to carbapenem (Amyes and Thomson, 1995).   
According to Walsh and Amyes (2004), antibiotic resistance has increased 
progressively in the past 20 years and is reaching a crisis because we are running out of 
options to treat certain pathogenic bacteria, mainly causing hospital-acquired infection but 
with the potential to occur in the community. Kuti et al. (2002) reported that the increasing 
emergence of multiresistant bacteria throughout the world and the lack of antibiotics to 
combat such pathogenic agents continue to be the major concern of the medical 
community. With the increase in drugs resistant among pathogens that happens because of 
not enough options to treat certain pathogenic bacteria, we can conclude that infections by 
the pathogens in human will also increase.   
Increase in fungal infection happens because the antifungal drugs are not very 
effective to treat fungal diseases. Casadevall et al. (2002) reported that fungal diseases are 
often difficult to diagnose and treat because antifungal drugs are often not very effective in 
the setting of impaired immunity. C. albicans can develop resistance to antimycotic drugs 
such as fluconazole which is often used to treat candidiasis. Hitchcock et al. (1993) 
reported that the frequency of multiazole-resistant strains belonging to Candida species 
other than Candida albicans is increasing.  
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This clearly proves that antibiotics or drugs resistance among pathogenic bacteria 
and fungi are the causes of infections in human. These are the reasons that influence the 
interest in the search for new antibiotics in research field. Palabiyikoglu et al. (2006) stated 
that although many of the older antibiotics remain effective, new drug development 
remains crucial owing to the increase in drug resistance among these important pathogens. 
Search for new antibiotics effective against multidrug resistant pathogenic bacteria is 
presently an important area of antibiotic research (Sitachitta et al., 1996) and the scope of 
search for various bioactive microbial products had, however, broadened (Berdy, 2005). 
New therapeutic agents are urgently needed to treat medical needs that are unmet (Zhang et 
al., 2005) and to combat the increasing incidences of resistant pathogenic organisms 
including fungi (Vikineswary et al., 1997). Casadevall et al. (2002) stated that there is 
considerable interest in the development of vaccines to prevent fungal diseases. This shows 
that older antibiotics can still be used. However, development of new antibiotic is important 
to improve the treatment of antimicrobial infections.  
In researching for new antibiotics, actinomycetes are now of interest because of its 
ability to produce bioactive compounds which are useful to be developed as new antibiotic. 
Okami and Hotta (1988) stated that actinomycetes are useful biological tools producing 
antimicrobials against bacteria. Actinomycetes are now of interest because they are the 
most economically and biotechnologically valuable prokaryotes (Lam, 2006). Other than 
that, Omura (1992) stated that actinomycetes are the most important source of bioactive 
metabolites. Ward and Bora (2006) stated that actinomycetes are the pre-eminent source of 
bioactive natural products. The bioactive metabolites or bioactive natural products derived 
from actinomycetes are useful compounds to be developed as new antibiotics to treat 
pathogenic organism infections.   
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 Actinomycetes produce a large amount of useful bioactive compounds. They are 
reported to be responsible for the production of about half of the discovered bioactive 
secondary metabolites (Berdy, 2005). The metabolites are reported as antibiotics (Berdy, 
2005; Strohl, 2004). Okami and Hotta (1988) reported that by the 1980, actinomycetes 
accounted for almost 70% of the world’s naturally occurring antibiotics. This clearly shows 
that actinomycetes have been proved to be the most important producers of a large amount 
of bioactive compounds which can be used as antibiotics.     
 Actinomycetes isolated from marine ecosystems are now of interest in antibiotic 
research field. Marine actinomycetes have been reported to be important producers of a 
wide range of bioactive compounds useful in the development of new antibiotics.  
Goodfellow and Haynes (1984) have suggested that actinomycetes found in the marine 
ecosystem have been relatively neglected and they may be viewed as a selected gene pool 
possibly containing organisms capable of producing useful metabolic substances.  
The bioactive compounds produced by marine actinomycetes are believed to differ 
from those produced by terrestrial actinomycetes because of the difference in the 
environmental conditions. Many of these metabolites (bioactive compounds) possess 
biological activities and have the potential to be developed as therapeutic agents (Lam, 
2006). 
 Actinomycetes have been frequently isolated from marine waters and sediments but 
they are given relatively little attention. They are largely unexplored as a source of 
bioactive agents for industrial production. Tan et al. (2004) also reported that actinomyetes 
isolated from marine organisms could possibly provide an alternative source of potential 
bioactive substances against those fungal pathogens. Jensen and Fenical (1996) reported 
that the production of useful compounds by actinomycetes from aquatic environments is 
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just beginning to be studied, but this area looks extremely promising.  This obviously 
shows that the research for new antibiotics from marine actinomycetes is now of interest.  
 
OBJECTIVES OF STUDY  
The objectives of this study were to: 
1) study the antibacterial and antifungal potentials of selected marine actinomycetes 
2) optimize media for the production of bioactive compounds 
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2 LITERATURE REVIEW 
2.1 General overview of actinomycetes  
Actinomycetes are Gram-positive bacteria. These bacteria were first regarded as 
fungi as early as 1878 (Srinivasan et al., 1991) because of the superficial similarity in the 
filaments between actinomycetes and fungi. However, actinomycetes are classified as true 
bacteria.  Srinivasan et al. (1991) also reported that it is firmly established that these 
organisms are prokaryotes with close affinities to the mycobacteria and the coryneforms 
and have no phylogenetic relationship with fungi. Das et al. (2006) reported that because of 
their well developed morphological and cultural characteristics, actinomycetes have been 
considered as a group well separated from common bacteria.  
This complex group of bacteria is prokaryotic organisms. They have cell wall but 
have no nuclear membrane. They reproduce by spores in two ways, either by fissions or by 
conidia. Actinomycetes are called filamentous bacteria because they form branching 
filaments or hyphae during their growth which resemble the mycelia of the fungi. However, 
their filaments are in the diameter of 1mikron(µ) which is smaller than those of the fungi. 
This distinguished the actinomycetes from the fungi. 
Actinomycetes belong to the kingdom bacteria ( Phylum: Actinobacteria, Class : 
actinobacteria). They can be divided into five subclasses Acidimicrobidae, 
Actinobacteridae, Coriobacteridae, Rubrobacteridae and Sphaerobacteridae.  
Williams et al. (1984) reported that these bacteria are primarily saprophytic. Most 
of the bacteria are aerobic and mesophilic. They are also heterotrophic organisms. The 
habitats of actinomycetes are wide spread in our environments.  
Zaitlin and Watson (2006) reported that actinomycetes are a complex group of 
bacteria present in a wide range of environments, either as dormant spores or actively 
growing. The common habitat of actinomycetes is soils. Imada (2005) reported that 
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actinomycetes are representative of terrestrial microorganisms and usually are isolated from 
soils. However, these bacteria can also be found in aquatic environments. Bull et al. (2005) 
reported that actinomycetes are very widely distributed in the world’s oceans. They are also 
reported to be easily isolated from the marine environment (Ward and Bora, 2006).  
Other than that, actinomycetes can also be found in marine organisms. Ward and 
Bora (2006) reported that actinomycetes are also present in many free-swimming marine 
vertebrates and invertebrates, as well as in sessile ones. They can be found living in marine 
organisms such as decaying marine algae, seaweed and sponges.  
Among the microorganisms, actinomycetes gained special importance due to their 
capacity to produce bioactive secondary metabolites and enzymes (Das et al., 2006). They 
are the most important producers of bioactive secondary metabolites. They produce 
vitamins, enzymes, antitumor agents, immunodefying agents and mainly antibiotic 
compounds (Goodfellow et al., 1988; Demain, 1995).  
Baltz (2007) reported that most antibiotics in clinical use are direct natural products 
or semisynthetic derivatives from actinomycetes or fungi. Many of those products, 
including erythromycin and derivatives, vancomycin and teicoplanin, cephalosporins, 
rifamicin, tetracyclines and daptomycin were discovered through whole-cell antibacterial 
screening procedures.   
The bioactive secondary metabolites are very useful. The secondary metabolites 
have the properties of interest in medicine and agriculture (Lechevalier, 1992). Other than 
that, the bioactive secondary metabolites are said to be of value to humans (Srinivasan et 
al., 1991). Lechevalier (1992) also stated that these metabolites will also continue to be 
starting points for drug design and chemical modifications. Tens of thousands of such 
compounds have been isolated and characterized, many of which have been developed into 
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drugs for treatment of a wide range of human diseases (Bull et al., 1992; Franco et al., 
1991).  
Of all the bioactive secondary metabolites produced by actinomycetes, antibiotics 
are the most important products. Mincer et al. (2002) stated that actinomycetes are best 
known as a source of antibiotics. They produce a very large amount of antibiotics. 
Takizawa et al. (1993) reported that approximately two-third of the thousands of naturally 
occurring antibiotics have been isolated from actinomycetes. Approximately 7000 of the 
compounds (antibiotics) reported in the Dictionary of Natural Products were produced by 
actinomycetes (Jensen et al., 2005). 
Because of their importance as producers of bioactive secondary metabolites 
especially antibiotics, actinomycetes have been the focus of many researches. They play an 
important role in pharmaceutical field as well as in biotechnology. Colquhoun et al. (2000) 
reported that in many areas of microbiology, there is a growing requirement for rapid and 
unambiguous characterization of organisms. Two situations for which this requirement is 
especially acute are in clinical diagnosis and biotechnology search and discovery programs 
due to failure of drug treatment, reinfection or relapse.  
 
2.2 Marine actinomycetes  
  Marine ecosystem is one of the habitats of actinomycetes. The world’s oceans 
include some of the most biodiverse ecosystems on the planet (Mincer et al., 2002), and 
provide the largest inhabitable space for living organisms, particularly microbes (Das et al., 
2006). Lam (2006) reported that recent culture-independent studies have shown that marine 
environments contain a high diversity of actinomycetes that are rarely, if at all, recovered 
by culture-dependent methods. Zaitlin and Watson (2006) reported that dormant spores of 
actinomycetes may be isolated from aquatic environments in high concentrations. 
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 Marine actinomycetes are always regarded as wash-in organisms. They were said to 
be transported from the terrestrial into the oceans. There have been reports of strains 
isolated from aquatic habitats are usually considered as wash-in organisms and, regarding 
longer periods, then living there in a dormant state (Bull et al., 2000; Cross, 1981). They 
are in many respects regarded as boundary bacteria (Weyland, 1986) and are merely of 
terrestrial origin (Mincer et al., 2002).  
 However, indigenous marine actinomycetes do occur in marine ecosystem. Bull et 
al. (2005) reported that truly indigenous marine actinomycetes have now been described. 
Recent findings confirm the presence of indigenous marine actinomycetes in the oceans and 
indicate that marine actinomycetes are widely distributed in different marine environments 
and habitats (Lam, 2006).  
 The habitats of actinomycetes in the marine ecosystem are wide spread. Ward and 
Bora (2006) reported that the actinomycetes, although not all the Actinobacteria, are easy to 
isolate from the marine environment. Lam (2006) reported that both culture-dependent and 
culture-independent methods demonstrate that novel actinomycetes can be found 
everywhere in the oceans – from the deep sea floor to coral reefs, from sediments to 
invertebrates and plants.  
 It has long been recognized that actinomycetes can be recovered from the sea 
(Weyland, 1969). Other than the open ocean, the actinomycetes can also be found in the sea 
sediments. There have been reports of actinomycetes recovered from the deep sea 
sediments (Zhang et al., 2005).  
 Actinomycetes can also be recovered from the mangroves. Zhang et al. (2005) 
reported of the isolation of actinomycetes from the mangroves. Weyland (1986) also 
reported that the mangroves exhibited the highest density of actinomycetes amongst the 
areas investigated also within their higher salinity regions.  
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 Other than that, actinomycetes can also be found living in marine organisms. There 
have been reports of actinomycetes isolated from marine organisms such as coral reefs 
(Zhang et al., 2005), from sponges (Sponga et al., 1999) and from seaweeds (Genilloud et 
al., 1994). Baltz (2007) reported that actinomycetes comprised about 10% of bacteria 
colonizing marine aggregates, and can be isolated from marine sediments, including those 
obtained at depths of 10898 m from the deepest part of the Marianas Trench. This 
obviously shows that actinomycetes are widespread in the marine ecosystem. Hence, the 
marine ecosystem must be explored in order to study the actinomycetes in deeper. 
 
2.3 The genus Streptomyces  
Streptomyces belong to the order Actinomycetales (Kingdom : Bacteria, Phylum : 
Actinobacteria, Subclass : Actinobacteridae, Family : Streptomycetaceae). Many 
researchers revealed that this group of actinomycetes species is the majority from many 
isolation programs. From 439 actinomycetes isolated, Zheng et al. (2000) reported that 
strains belonging to the genera Streptomyces and Micromonospora, especially the former, 
represented the majority. Other than that, Kitouni et al. (2005) also reported that from their 
studies 93% of active actinomycetes belong to Streptomyces genus. This obviously shows 
that Streptomyces genus is the most prolific group of actinomycetes. More than that, 
Weyland (1986) also reported that from their studies the bulk of the isolates from sea 
sediments could be classified only in three taxonomic groups: streptomycetes, 
Micromonospora and nocardioforms.  
The species in the genus Streptomyces, as with the other actinobacteria, are Gram-
positive organisms. They are also aerobic and filamentous bacteria. They are saphrophytic 
and not highly pathogenic, but are associated with inflammatory disorders of the airways, 
and possibly other symptoms of an autoimmune character (Huttunen et al., 2002).  
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The Streptomyces sp. produces substrate mycelium and aerial mycelium. Francisco 
and Silvey, (1971) reported that Streptomyces substrate mycelium is described as 
facultatively aerobic while the aerial growth was obligately aerobic. Rintala (2003) reported 
that the streptomycetes are aerobic, Gram-positive bacteria, which produce extensive 
branching vegetative (substrate) mycelium and aerial mycelium bearing chains of 
arthrospores. Specifically, the organism produced abundant gray-white aerial mycelium, 
which transformed into chains of smooth, cylindrical arthrospores, as shown by scanning-
electron microscopy (Sitachitta et. al., 1996).  
 Getha et al. (2007) reported that the streptomycete-like group formed substrate 
mycelium and abundant aerial mycelium with powdery spore mass. The occurrence of 
distinct aerial mycelium with abundant spore mass formation represents an important 
macroscopic criterion to identify the genus Streptomyces. They can be differentiated from 
other actinomycetes genera that also produce aerial mycelium by other morphological, 
biochemical and physiological properties (Goodfellow and Williams, 1983).    
The substrate mycelium and spores can be pigmented. However, diffusible pigments 
are also produced. On agar plates, they form lichenoid, leathery butyrons colonies 
(Williams et al., 1989). 
The genus Streptomyces are widespread in the marine environment. They can be 
found in coastal and shelf regions (Weyland, 1986). In previous studies enumerating 
culturable Streptomyces isolates in marine ecosystems, the majority of isolates were 
recovered from coastal environments, such as shallow seas, mangrove swamps, or sea grass 
communities (Rehnstam et al., 1993).  
Among all Actinobacteria, the genus Streptomyces is regarded as the most potent 
producers of bioactive secondary metabolites. After the discovery of streptomycin and later 
chloramphenicol, tetracyclins and macrolides the attention turned to the Streptomyces 
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species. Streptomyces in the family Streptomycetacae (Stackebrandt et al., 1997) is one of 
the most prolific producers of secondary metabolites. Sanglier et al. (1993) reported 
between 1988 and 1992, more than a hundred new molecules from actinomycetes were 
discovered. Approximately 75% of these originated from the Streptomyces genus and at 
least 5000 documented bioactive compounds are known as being produced by this genus 
(Anderson and Wellington, 2001). In fact, the genus Streptomyces also accounts for a 
remarkable 80% of the actinomycetes natural products reported to date, a biosynthetic 
capacity that remains without rival in the microbial world (Jensen et al., 2005). Wagner et 
al. (2002) reported that most secondary metabolites from marine microorganisms found so 
far were isolated from Streptomyces and Alteromonas sp.  
The bioactive secondary metabolites are very useful. The metabolites have different 
functions which is very useful to human life. The bioactive secondary metabolites produced 
by the Streptomyces genus have different biological activities such as antibacterial and 
antifungal activities (Demain, 1999). Miyadoh (1993) reported that the Streptomyces 
species produce about 75% commercially and medically useful antibiotics. Out of the 
approximately 10000 known antibiotics, 45-55% are produced by streptomycetes (Demain, 
1999; Lazzarini et al., 2000). The secondary metabolites produced by them have a broad 
spectrum of biological activities such as antibacterial (streptomycin, tetracycline, 
chloramphenicol) and antifungal (nystatin) (Rintala, 2003).   
Peela et al. (2005) reported that from 88 actinomycete strains isolated from marine 
sediments collected near nine islands of the Andaman coast of the Bay of Bengal, 64 
isolates were identified as belonging to the genus Streptomyces, family Streptomycetaceae 
(spore chain with coiling and branching). Other than that, Berdy (2005) reported that 
obviously various actinomycetales, first of all the Streptomyces species and filamentous 
fungi, and to a lesser extent several bacterial species are the most noteworthy producers 
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both in respect of numbers, versatility and diversity of structures of the produced 
metabolites.  
This obviously shows that the genus Streptomyces are abundant in our ecosystem. 
They are the majority species isolated by many researchers. They are also regarded as the 
most important producers of bioactive secondary metabolites especially antibacterial and 
antifungal. The bioactive secondary metabolites are very useful in human life where they 
can be developed to treat infectious diseases.  
  
2.4    Marine actinomycetes as a source of bioactive metabolites  
Marine actinomycetes produce many useful bioactive metabolites. They have been 
reported to produce highly active substances and are regarded as the most important source 
of bioactive metabolites. Mincer et al. (2002) reported that despite their importance in soil 
ecology, actinomycetes are best known as a source of antibiotics. More than that, Osada 
(1998) and Saadoun and Gharaibeh (2003) also reported that actinomycetes are prolific 
producers of antibiotics and other industrially useful secondary metabolites such as 
antibiotics, herbicides, pesticides and anti-parasitic. Actinomyctes have long been tapped 
by pharmaceutical researchers as a source of novel antibiotics, actinomycin and 
streptomycin for instance (Rintala, 2003).  
  Fiedler et al. (2005) reported that in contrast to marine invertebrates, marine 
bacteria seem to be a promising source as producers of drug candidates. They focused their 
investigations solely on marine microorganisms whose biotechnological production process 
can easily be scaled-up, as in the case of the bacterial order Actinomycetales. Other than 
that, Jensen et al. (2005) reported that marine-adapted actinomycetes produce a relatively 
high rate of new secondary metabolites and that these bacteria do in fact represent a natural 
product resource worthy of thorough exploration. 
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The filamentous actinomycetes account for a significant fraction of microbial 
metabolite (Busti et al., 2006). Microbial extracts could be developed into useful drugs to 
treat infectious diseases. Microbial extracts have been and continue to be a productive 
source of new biologically active molecules for drug discovery (Cragg et al., 1997; Shu, 
1998). It is estimated that more than 30% of worldwide human pharmaceutical sales have 
compounds from natural sources as their origin (Schmid et al., 1999). More than 70% of 
antibiotics (including not only antibacterial agents but also bioactive microbial compounds) 
have been reported to be produced by actinomycetes, which were composed of the genus 
Streptomyces (68%) and the rare actinomycetes (32%) (Miyadoh, 1993). More than 720 
marine metabolites were reported in the literature during 2003, about half of which 
demonstrated biological activities (Zhang et al., 2005). 
This shows that marine actinomycetes are the most important producers of bioactive 
secondary metabolites. The bioactive secondary metabolites have been developed into 
useful pharmaceutical products. The products could be used to treat infectious diseases in 
human.  
     
2.4.1 Bioactive metabolites  
Bioactive metabolites are secondary metabolites. Berdy (2005) reported that the 
secondary metabolites are low molecular (MW<3000), chemically and taxonomically 
extremely diverse compounds with obscure function, characteristic mainly to some 
specific; distinct types of organisms.  
The most characteristic features are their incredible array of unique chemical 
structures and their very frequent occurrence and versatile bioactivities. The presently 
known secondary microbial metabolites, exhibit a great numbers of diverse and versatile 
biological effects, first of all antimicrobial activities. Some 60% of the presently known 
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bioactive microbial metabolites, about 14000 compounds exhibit antimicrobial 
(antibacterial, antifungal) (Demain and Fang, 2000). Berdy (2005) reported that the 
presently known secondary microbial metabolites, exhibit a great numbers of diverse and 
versatile biological effects, first of all antimicrobial activities.  
In a broad sense, antibiotics include any chemical of natural origin, which has the 
effect on the growth of other types of cells. They are antimicrobial agents secreted by 
microorganisms that kill or inhibit other microorganisms. They are secondary molecules 
(produced only when needed) (Dairi et al., 1999). Srinivasan et al. (1991) reported that 
antibiotics are secondary metabolites and, while they have no physiological role in the 
growth phase of the actinomycete culture, they are produced as idiophase metabolites after 
the active growth phase is over.  
Antibiotics are produced as secondary metabolites by certain groups of 
microorganisms, especially streptomycetes. Over 6000 of these compounds are produced 
by Streptomyces species and many are commercially important medicinal products used 
therapeutically as anti-infective (antibiotic, antifungal and antiparasitic), anticancer or 
immunosuppressant agents (Takahashi and Mura, 2003). Antibiotics may have a 
bactericidal(killing) effect or a bacteriostatic(inhibitory) effect on a range of microbes. 
 Zheng et al. (2000) reported that as a great promising source for new natural 
products which have not been observed from terrestrial microorganisms, marine bacteria 
are being developed for the discovery of bioactive substances with new types of structure, 
with growing intensive interest. The achievements have been well reviewed (Jensen and 
Fenical, 1994; Bernan et al., 1997), where many new antibiotics were obtained from 
actinomycetes. Selvin et al. (2004) reported that many bacteria and cyanobacteria 
associated with sponges were found to be the sources of antibiotics and other bioactive 
compounds in marine environment. 
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 From this, we can conclude that actinomycetes are wide spread in our environment. 
They are regarded as potent producers of bioactive secondary metabolites. Recently, the 
marine actinomycetes have become the focus of studies. Marine actinomycetes are also 
widespread in the marine ecosystem. Marine actinomycetes are also regarded as the most 
important producers of bioactive secondary metabolites.  
 The bioactive secondary metabolites are very important especially in the 
pharmaceutical fields. The metabolites can be developed into useful pharmaceutical 
products which can be used to treat emerging and re-emerging infectious diseases in 
human. This helps to improve the human health as well as extend human life.  
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3 MATERIALS AND METHODS 
3.1   Test actinomycetes   
The actinomycetes used in this study were obtained from Prof. Dr. Vikineswary 
Sabaratnam from Plant Mycology and Pathology Laboratory, Institute of Postgraduate 
Studies, University of Malaya (IPS, UM). The actinomycetes were identified as putative 
Streptomyces spp. and 11 strains were selected for further studies. Table 3.1 shows the 
selected putative strains of Streptomyces spp. Figures 3.1 a – k shows the cultures of 
selected putative Streptomyces spp.  
 
Table 3.1: Selected putative strains of Streptomyces spp. for bioactivity screening on 
inorganic salts-starch agar (ISP4) for strains T3 and T4 and sporulation 
agar (SA) for the remaining strains 
Media Code of strains Colour groups  
ISP4 
T3 
Grey 
T4 
SA 
T9 
White/Red 
T12 
T13 
T15 
T52 
T6 
White/Brown 
T16 
T20 
T53 
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a) Strain T3      b) Strain T4         c) Strain T6  
  
            
            
            
            
            
     
 
 
 
d) Strain T9                  e) Strain T12                   f) Strain T13  
       
            
            
            
            
 
 
 
 
 
g) Strain T15         h) Strain T16         i) Strain T20   
 
 
     
 
 
 
 
 
 
 
j) Strain T52       k) Strain T53 
 
 
 
 
 
 
 
 
Figure 3.1: Cultures of selected putative strains of Streptomyces spp. for bioactivity 
screening incubated at 28±2oC for 7 – 14 days on ISP4 for strains T3 and 
T4 and SA for the remaining strains 
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3.1.1 Preparation of stock cultures   
 The colonies to be preserved were selected from the agar culture with heavy growth. 
The agar culture was aseptically cut into small 0.5x0.5mm pieces using sterilized loop. The 
plugs were then transferred into sterilized Bijou bottles containing 4ml of 30% (v/v) 
glycerol (Wellington and Williams, 1978) (Appendix A, 1). The stock cultures were then 
stored at -20±2oC. For each actinomycetes strain, the stock cultures were prepared in 
triplicates.  
 
3.1.2 Preparation of pure cultures   
 Pure cultures of actinomycetes strains could be prepared using the stock cultures. 
The frozen stock cultures were left at 10±2oC overnight and then brought to room 
temperature before it was used to prepare pure cultures. The plugs were removed from the 
glycerol stock using a sterilized loop and transferred to growth media on agar plates. The 
actinomycetes strains were then streaked on the surface of the growth media. 
Actinomycetes strains T3 and T4 were streaked on inorganic salts-starch agar (ISP4) 
(Appendix A, 2). The remaining strains were streaked on sporulation agar (SA) (Appendix 
A, 3). The plates were then incubated at 28±2oC for 7-14 days. The pure cultures were also 
prepared in triplicates for each actinomycetes strain.  
 
3.2   Test microorganisms 
The test microorganisms used in this study were divided into two groups, the 
pathogenic bacteria and fungi. The pathogenic bacteria, Enterobacter faecalis, 
Staphylococcus aureus, Bacillus subtilis, Pleisiomonas shigelloides and Pseudomonas 
aeruginosa were obtained from Prof. Dr. Thong Kwai Lin from the Institute of 
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Test microorganisms 
(4-5 streaks) with 
about 0.5-1cm from 
the border of the 
actinomycetes 
 
Actinomycetes strains  
Postgraduate Studies, University of Malaya (IPS, UM). The fungi, Candida parapsilosis 
and Candida albicans were obtained from Prof. Ng Kee Peng.  
The pathogenic bacteria were grown on nutrient agar (NA) (Appendix A, 4) and 
incubated at 37±2oC for 24 hours. Yeasts were grown on Sabaroud-dextrose agar (SDA) 
(Appendix A, 5) at 37±2oC for 24 hours.  
 
3.3   Primary screening    
Primary screening by the cross streak method was carried out in this study. The 
actinomycetes strains were streaked on approximately one third of the agar plates, ISP4 for 
actinomycetes strains T3 and T4 and SA for the remaining strains. The plates were then 
incubated at 28±2oC for 7-14 days. After the incubation period, single colonies of two days 
old test microorganisms were cross streaked perpendicular to actinomycetes strains on the 
test plates. About 4 to 5 streaks of test microorganisms were streaked at about 0.5-1.0cm 
from the border of the actinomycetes. Figure 1 shows the cross streak method for primary 
screening. Positive control plates for the test were prepared by streaking only the test 
microorganisms on the agar plates, without the actinomycetes.  
 After cross streak, the plates were incubated for 48 hours at 37±2oC. After the 
incubation period, the inhibition of the test microorganisms’ growth was observed. The 
degrees of the inhibition were recorded.  
 
 
 
 
 
Figure 1. Cross streak method for primary screening 
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3.4   Secondary screening  
 Secondary screening by diffusion using paper disc method was carried out in this 
study. The strains were cultivated in submerged cultures. The fermentation media ISP4 for 
strains T3 and T4 and SA for the remaining strains were prepared without the agar in the 
250ml Erlenmeyer flasks. The surface of the agar plates with dense growth of 
actinomycetes strains were scraped using sterilized loop and transferred into 10ml sterilized 
distilled water in the small conical flasks. The mixture was then transferred into 90ml 
(90%) sterilized fermentation media using sterilized pipette. T3 and T4 were cultivated in 
ISP4, and the remaining actinomycetes strains were cultivated in SA. The flasks were than 
incubated on a rotary shaker at 120rpm, 28±2oC for 7-14 days.  
After the incubation period, the submerged cultures were transferred into round 
bottom flasks. The flasks were coated using dry ice. Freeze dry using Beta 1-8 Freeze 
Dryer was applied in order to get rid of water in the submerged cultures. The freeze dried 
materials were then transferred into 250ml Erlenmeyer flasks. 50ml of dichloromethane 
(DCM) and 50ml of methanol with the ratio of 1:1 were added into the flasks. The mixtures 
were than left overnight on the rotary shaker at 120rpm at 28±2oC.  
The mixtures were then sonicated using Ultrasonic Bath at 40 kHz for 30 minutes at 
room temperature. Sonication was done to break up the actinomycetes cells.   
After sonication, the mixtures were filtered using sterilized Whatman filter paper to 
get the culture filtrates. The culture filtrates were then dried using a rotary evaporator at 50-
55oC. This process was done to get the crude extracts of the actinomycetes strains. 
The crude extracts were dissolved in methanol. For every 25mg of the crude 
extracts, 1ml of methanol was added. The crude extracts could be kept at -20oC. They were 
tested for its bioactivity within one to two weeks (Tan et al., 2004).  
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Sterilized Whatman 6mm paper discs were used. Test microorganisms were first 
lawned on the surface of the agar media in the test plates. The pathogenic bacteria were 
lawned on NA while the pathogenic fungi were lawned on SDA. After that, five sterilized 
Whatman paper discs were placed on the surface of the seeded plates. 15µl of the dissolved 
crude extract were loaded on four of the paper discs. The paper discs at the center of the 
plates were loaded with methanol. Paper discs loaded with methanol were assigned as 
negative control.  Ready made antibiotics discs were used as positive control. Novobiocin 
and streptomycin discs were used as antibacterial test while nystatin disc was used as 
antifungal test. The test plates were then incubated for 24 hours 37±2oC. 
 After 24hours, the diameter of the inhibition zone around the paper discs was 
observed. The clearance around the paper discs showed that the test microorganisms’ 
growth was inhibited by the actinomycetes strains. The diameter of the inhibition zone was 
recorded. Figure 2 shows the flow diagram of procedures for secondary screening of 
actinomycetes strains. 
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Figure 2: Flow diagram of procedures for secondary screening of actinomycetes 
strains 
 
10ml of actinomycetes spore suspension 
           + 
90ml (90%) sterilized fermentation media 
                                                                      Incubated on a rotary shaker at 120rpm, 
28±2oC, 7-14 days   
Transferred to round bottom flasks 
  
 
Freeze dried 
                   24 hours 
 
Freeze dried materials were soaked in DCM : Methanol (v/v, 1:1) 
                                                                      Incubated on a rotary shaker at  
                                                               120rpm,28±2oC, overnight  
Sonicated in Ultrasonic Bath  
                                                             40kHz, Room temperature, 30min 
 
Filtration using Whatman 6mm filter paper 
 
 
Culture filtrates were dried using a rotary evaporator at 50-55oC 
 
 
Crude extracts were redissolved in methanol 
 
 
Crude extracts were kept at -20oC 
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3.5   Media optimization   
 In optimization of media for production of bioactive compounds, only one 
Streptomyces sp. was selected and tested against one selected test microorganism. In this 
study, the Streptomyces sp. selected was strain T53. The strain was tested against 
pathogenic bacteria, E. faecalis.  
 In media optimization, only secondary screening method was applied. The 
processes applied were as mentioned earlier (Chapter 3, Section 3.4, page 24 – 25). 
Howevernthree growth media in liquid form were used. The growth media were yeast 
extract-malt extract agar (ISP2) (Appendix A, 6), ISP4 and SA. Dimethylsulfoxide 
(DMSO) was used as a solvent.  
In optimization of media for production of bioactive compounds, submerged culture 
fermentation was carried out in two conditions, static and agitation. For each of the growth 
medium, twelve flasks of the submerged cultures were prepared in 250ml Erlenmeyer 
flasks. For submerged culture fermentation in static condition, the cultures were incubated 
at 28±2oC for twelve days without agitation. On the other hand, submerged cultures 
fermentation in agitation condition were incubated at 28±2oC for twelve days and agitated 
at 120rpm. 
 Every three days, three flasks were taken out. The pH of the cultures was recorded. 
The submerged cultures were processed as mentioned earlier (Chapter 3, Section 3.4, page 
24 – 25) to get crude extracts. The crude extracts were used to test for antibacterial 
activities of the actinomycetes strain using the paper disc method. Ready made 
streptomycin disc and novobiocin disc were used as positive control for the test. The 
diameter of the inhibition zone around the paper discs was observed and recorded.  
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4 RESULTS AND DISCUSSIONS 
4.1 Antagonistic pattern in primary and secondary screening  
Table 4.1 shows the antibacterial and antifungal activities of selected Streptomyces 
spp. in primary and secondary screening. The number of active Streptomyces spp. against 
test bacteria was higher in secondary screening compared to primary screening. However, 
the number of active strains against test fungi was higher in secondary screening compared 
to primary screening.  
 
Table 4.1: Antibacterial and antifungal activities of selected Streptomyces spp. in 
primary and secondary screening   
  Number of active strainsa  
Antibacterialb  
Primary screeningd 9  
Secondary screeninge 11 
Antifungalc  
Primary screening 0 
Secondary screening 7 
a Number of active strains antagonistic against at least one test microorganism in primary and  secondary 
screening. Total strains tested for bioactivity were eleven; b Antibacterial activity against: E. faecalis, S. 
aureus, P. shigelloides, B. subtilis and  P. aeruginosa; c Antifungal activity against: C. parapsilosis and C. 
albicans; d Primary screening: Cross streak method was applied on ISP4 for T3 and T4 and SA for the 
remaining strains. The plates were incubated for 48 hours at 37±2oC; e Secondary screening: Paper disc 
method was applied on NA for test bacteria and on SDA for test fungi. The discs were loaded with 15µl of 
crude extracts and the plates were incubated for 24 hours at 37±2oC.   
 
 In primary screening, nine strains showed antagonistic activity against at least one 
test pathogenic bacteria. However, no antifungal activity was recorded against the test 
fungi. In secondary screening, all strains showed antagonistic activity against at least one 
test pathogenic bacteria. The antifungal activity was also recorded where seven strains 
showed antagonistic activity against at least one test fungi.  
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4.1.1 Antibacterial activity 
 Table 4.2 shows the antibacterial activity of selected Streptomyces spp. against test 
bacteria in primary and secondary screening. Total number of Streptomyces spp. tested for 
antagonistic activity against test bacteria was eleven. Antibacterial activity against test 
bacteria was recorded in both primary and secondary screening. The antibacterial activity 
was recorded against both Gram-positive bacteria and Gram-negative bacteria.  
  
Table 4.2: Antibacterial activity of selected Streptomyces spp. against test bacteria in 
primary and secondary screening  
                          Antagonistic activity 
 
Test bacteria 
Primary screeninga Secondary screeningb 
Number of active 
strains 
Number of active 
strains 
Gram-positive 
bacteria 
E. faecalis 8 11 
S. aureus 6 11 
B. subtilis 6 11 
Gram-negative 
bacteria 
P. shigelloides 6 11 
P. aeruginosa 7 4 
a Primary screening: Cross streak method was applied on ISP4 for T3 and T4 and SA for the remaining 
strains. The plates were incubated for 48 hours at 37±2oC; b Secondary screening: Paper disc method was 
applied on NA agar medium. The discs were loaded with 15µl of crude extracts and the plates were incubated 
for 24 hours at 37±2oC.  
 
The number of active strains against test bacteria was higher in secondary screening 
compared to primary screening (Table 4.1). In primary screening, eight strains showed 
antagonistic activity against E. faecalis. Seven strains showed antagonistic activity against 
P. aeruginosa and six strains showed antagonistic activity against S. aureus, B. subtilis and 
P. shigelloides.  
 In secondary screening, the number of active strains against all Gram-positive 
bacteria increased. All strains showed antagonistic activity against the Gram-positive 
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bacteria. The number of active strains against P. shigelloides also increased. All strains 
showed antagonistic activity against the pathogen. However, the number of active strains 
against P. aeruginosa decreased to only four strains. In this study, the antagonistic pattern 
of P. aeruginosa was not similar with other test bacteria. The antagonistic activity against 
the pathogen was higher in primary screening compared to secondary screening.   
Table 4.3 shows the antibacterial activity of selected Streptomyces spp. against test 
bacteria in secondary screening. The inhibition zones around the paper discs mounted with 
crude extracts of selected Streptomyces spp. was recorded. In this study, the degree of 
inhibition zones were grouped into weak (<10mm), moderate (10-15mm) and good 
(>15mm). Most of the active strains exhibited weak inhibition against all test bacteria. A 
few active strains exhibited moderate inhibition against all test bacteria except E. faecalis. 
Good inhibition was only recorded against E. faecalis and P. shigelloides.  
Ten strains showed weak inhibition against E. faecalis and S. aureus. Nine strains 
showed weak inhibition against B. subtilis. Seven and three strains showed weak inhibition 
against P. shigelloides and P. aeruginosa, respectively. Moderate inhibition by one active 
strain was recorded against S. aureus. One strain also showed moderate inhibition against 
P. aeruginosa. Two strains showed moderate inhibition against B. subtilis and P. 
shigelloides. Active strains only showed good inhibition against E. faecalis and P. 
shigelloides. One strain showed good inhibition against E. faecalis. Two strains showed 
good inhibition against P. shigelloides.  
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Table 4.3: Antibacterial activity of selected Streptomyces spp. against test bacteria in 
secondary screening on NA for 24 hours at 37±2oC 
Antagonistic activity 
 
 
 
Test bacteria 
Total 
number of 
active  
strains 
Weak  
(<10mm) 
Moderate  
(10 – 15mm) 
Good 
(>15mm)  
Number of 
active 
strains  
Number of 
active 
strains  
Number of 
active 
strains  
Gram-
positive 
bacteria 
E. faecalis 11 10  - 1  
S. aureus 11 10  1  - 
B. subtilis 11 9  2  - 
Gram-
negative 
bacteria 
P. shigelloides 11 7  2  2  
P. aeruginosa 4 3  1  - 
 
In this study, the percentage of active strains that exhibited antibacterial activity 
against at least one test bacteria was higher in secondary screening than in primary 
screening. This is in agreement with the study done by Kavithambigai (2006). The author 
reported that the antibacterial activity was prominent in secondary screening (54.6%). In 
her study, the percentage of active strains that exhibited antibacterial activity against at 
least one test bacteria from root samples collected in Kuantan was higher in secondary 
screening (58.3%) than in primary screening (43.2%). The author also reported that the 
percentage of active strains from Port Dickson mangrove was also higher in secondary 
screening (51.4%) than in primary screening (31.1%).   
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Peela et al. (2005) reported that 44% of marine actinomycetes isolated from the Bay 
of Bengal showed antibacterial activity. Tan et al. (2004) reported that 25 (51%) out of 49 
crude extracts of actinomycetes exhibited inhibition against at least one test bacteria. The 
ability of actinomycetes exhibiting antibacterial activity was once again proved in the 
present study. Antimicrobial compounds work against bacteria by way of a variety of 
mechanisms. Antimicrobial agents act by interfering with cell wall synthesis, cell 
membrane function, nucleic acid synthesis, ribosomal function and folate synthesis. Cell 
wall synthesis can be affected either by preventing the production of new cell walls, 
effectively stopping the cell from reproducing, or by providing analogues for the bacteria to 
include as the new cell is produced, leading to cell lysis and death (Appelbaum and Jacobs, 
2005). 
Tan et al. (2004) reported that seven strains of actinomycetes exhibited broad 
spectrum inhibition against both Gram-positive and Gram-negative bacteria. Seventeen 
(68%) out of the 25 strains inhibited Gram-positive test bacteria and one (4%) inhibited 
Gram-negative test bacteria. Selvin et al. (2004) reported that the extracellular products 
(ECPs) of Streptomyces sp. strain BTL7 isolated from marine sponge, Dendrilla nigra 
successfully prevented the growth of the Gram-positive bacteria to the extent of 60% 
whereas the inhibitory potential was decreased towards the Gram-negative bacteria (40%). 
Zheng et al. (2000) reported that eleven (65%) out of seventeen tested strains showed 
antibacterial activity against Gram-positive bacteria, eight (47%) against Gram-negative 
bacteria and four (23.5%) against both Gram-positive and Gram-negative bacteria. Bernan 
et al. (1994) reported that the extracellular proteins (ECPs) of actinomycete strain (LL-
31F508) isolated form an intertidal sediment collected in Key West, Florida, showed potent 
antimicrobial activity against Staphylococcus spp. and Enterococcus spp. Pisano et al. 
(1992) reported that 68% out of 85 marine actinomycetes capable of degrading chitin 
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exhibited antibacterial activity against Gram-positive bacteria. Only 11% of the 
actinomycetes were active against Gram-negative bacteria. This is in agreement with the 
results obtained in the present study because the antibacterial activity was prominent 
against Gram-positive bacteria compared to Gram-negative bacteria. 
Sujatha et al. (2005) reported that streptomycete strain BT-408 showed a broad 
spectrum against Gram-positive and Gram-negative bacteria, fungi and yeast including the 
pathogenic methicillin resistant S. aureus when tested with crude culture filtrates and also 
with purified antibiotic SBR-22. Peela et al. (2005) reported that Streptomyces sp strains 
BT606 and BT652 showed antimicrobial activites against S. aureus and P. aeruginosa. 
Thorne and Alder (2002) reported that Streptomyces roseosporus produced Daptomycin 
which exhibited antibacterial activity against S. aureus. Kavithambigai (2006) reported that 
in secondary screening, the percentage of active strains against Gram-positive bacteria 
increased to 48.2% and 39.8% for B. subtilis and S. aureus, respectively. This is again in 
agreement with the result obtained in the present study because test actinomycetes 
exhibited antibacterial activity against Gram-positive bacteria including S. aureus and B. 
subtilis.  
Pisano et al. (1986) reported that from their studies, 19 strains of actinomycetes 
isolated from marine sediments in Sandy Hook Bay, New Jersey displayed antimicrobial 
activity. The most prominent inhibitory activity noted was directed against Gram-positive 
bacteria (S. aureus and B. subtilis). All of the actinomycetes displayed significant inhibition 
of B. subtilis and 12 inhibited the growth of S. aureus, whereas only one inhibited P. 
aeruginosa. This is in agreement with the results obtained in the present study because 
prominent inhibitory activity was also noted against Gram-positive bacteria (S. aureus and 
B. subtilis).  
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Kavithambigai (2006) reported that in secondary screening, the number of active 
strains against P. aeruginosa decreased (4.0%). The author also reported that 50% of active 
strains showed weak antibiosis (inhibition zone in between 8-10mm) against P. aeruginosa. 
This is in agreement with the result obtained in the present study. In this study, the 
antagonistic activity against P. aeruginosa decreased from 7 strains in primary screening to 
4 strains in secondary screening. Present study also showed that active strains exhibited 
weak inhibition zone against P. aeruginosa. 
Present study showed that majority of active strains exhibited weak inhibition 
against B. subtilis and S. aureus. This result, however, is not in agreement with the results 
obtained by Kavithambigai (2006) because the majority of active strains showed moderate 
antibiosis (inhibition zone in between 11-20mm) against B. subtilis (54.5%) and S. aureus 
(54.1%). The author also reported that 25% of active strains showed good antibiosis 
(inhibition zone more than 20mm) against B. subtilis and 16.2% against S. aureus. This 
might suggests that the marine actinomycetes might not have the same antibacterial activity 
with the actinomycetes isolated from root samples. During the screening of the novel 
secondary metabolite, actinomycetes isolates are often encountered which show antibiotic 
activity on agar but not in liquid culture. This might explain the higher number of 
antibacterial activity against P. aeruginosa in primary screening compared to secondary 
screening in this study.  
According to Kokare et al. (2004) during the screening of the novel secondary 
metabolite, actinomycetes isolates are often encountered which show more active 
antimicrobial activity against Gram-positive bacteria than Gram-negative bacteria. Pandey 
et al. (2006) reported that the reason for different sensitivity between Gram-positive and 
Gram-negative bacteria could be ascribed to the morphological differences between these 
microorganisms, Gram-negative bacteria having an outer polysaccharide membrane 
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carrying the structural lipopolysaccharide components. This makes the cell wall 
impermeable to lipophilic solutes. On the other hand, the Gram-positive bacteria only have 
an outer peptidoglycan layer. Brock et al. (1994) reported that porins structure that situated 
in outer membrane of Gram-negative bacteria serve as membrane channels for the entrance 
and exit of hydrophilic low-molecular weight substances. When the structure comes in 
contact with high molecular antibiotics, such porins can be closed to prevent antibiotic. 
This increased the resistance of Gram-negative bacteria to antibiotics. This explains the 
higher number of active strains against Gram-positive bacteria compared to Gram-negative 
bacteria.   
Pisano et al. (1989) reported that 68 (46%) out of 147 strains of actinomycetes 
isolated from the sediments of the south shore of Brooklyn, the East River and New Jersey 
exhibited antimicrobial activity. Most of the inhibitory activity was directed against Gram-
positive bacteria. B. subtilis was the most susceptible, followed closely by S. aureus. 
Activity against Gram-negative bacteria was minimal with only eight or 5% of the isolates 
proving effective. Only one strain (strain SG-944) inhibited the growth of P. aeruginosa.  
41(28%) of the isolates was inhibitory to one or more of the fungal test species. Pisano et 
al. (1992) reported that B. subtilis was inhibited by 58% of the active marine actinomycetes 
strains, S. aureus by 50%, P. aeruginosa by 5% and C. albicans by 32%.  
According to Kavithambigai (2006), the antibacterial activity might be stimulated 
by intracellular metabolites, which were bound inside membrane of actinomycetes and 
released during submerged cultivation. This explains the higher number of antibacterial and 
antifungal activity in secondary screening compared to primary screening. 
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4.1.2 Antifungal activity 
 Table 4.4 shows the antifungal activity of selected Streptomyces spp. against test 
fungi in primary and secondary screening. Total number of Streptomyces spp. tested for 
antagonistic activity against test fungi was eleven. Antifungal activity was only recorded in 
secondary screening. In primary screening, selected Streptomyces spp. did not inhibit the 
test fungi.  
 
Table 4.4: Antifungal activity of selected Streptomyces spp. against test fungi in 
primary and secondary screening 
  Antagonistic  
activity 
Test fungi   
Primary screeninga Secondary screeningb 
Number of active strains Number of active strains  
C. parapsilosis - 7  
C. albicans - 4 
a Primary screening: Cross streak method was applied on SA agar medium and the plates were incubated for 
48 hours at 37±2oC; b Secondary screening: Paper disc method was applied on SDA agar medium. The discs 
were loaded with 15µl of crude extracts and the plates were incubated for 24 hours at 37±2oC. 
 
In secondary screening, seven strains showed antagonistic activity against C. 
parapsilosis. Four strains showed antagonistic activity against C. albicans. Table 4.5 shows 
the antifungal activity of selected Streptomyces spp. against test fungi in secondary 
screening. All active strains exhibited weak inhibition against the test fungi.  
The number of active strains that showed weak inhibition against C. parapsilosis 
was seven. Four strains showed weak inhibition against C. albicans. The most susceptible 
fungal was C. parapsilosis. 
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Table 4.5: Antifungal activity of selected Streptomyces spp. against test fungi in 
secondary screening on SDA for 24 hours at 37±2oC 
Antagonistic 
activity 
 
 
 
Test fungi 
Total number 
of active strains 
Weak  
(<10mm) 
Moderate   
(10 – 15mm) 
Good 
(>15mm) 
Number of 
active strains 
Number of 
active strains  
Number of 
active strains  
C. parapsilosis 7 7  - - 
C. albicans  4 4  - - 
  
Present study also showed that active strains exhibited higher percentage of 
antifungal activity against at least one test fungi in secondary screening than in primary 
screening. This is however not in agreement with the study done by Kavithambigai (2006). 
The author reported that active strains exhibited higher antifungal activity in primary 
screening for both root samples from Kuantan (69.7%) and Port Dickson (59.7%). This 
might suggest that marine actinomycetes might not have the same antifungal substance with 
the actinomycetes isolated from root samples.  
Kavithambigai (2006) reported that antifungal activity was prominent in secondary 
screening. The antifungal activity was more prominent on phytopathogenic fungi (F. 
oxysporum cubense race 1; 26.1%, F. oxysporum cubense race 2; 30.4%, F. oxysporum 
cubense race 4; 30.4%, Colletotrichum sp.; 21.7%, G. boninense ; 31.5%) compared to C. 
albicans (11.6%) and C. parapsilosis (9.8%). Most of the active strains showed moderate 
antibiosis (inhibition in between 11-20mm) against C. albicans (83.3%) and C. parapsilosis 
(58.8%).  Atta and Ahmad (2009) reported that an actinomycete culture was isolated from a 
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soil sample collected from Alam Alroom districted, Marsa Matrouh governorate, Egypt. 
This isolate AZ-AR-262 was found to be active against unicellular and filamentous fungi. 
Peela et al. (2005) reported that Streptomyces sp. strains BT606 and BT624 were 
active against C. albicans. Tan et al. (2004) reported that 15 (31%) of 49 crude extracts 
tested exhibited inhibition against the test fungi including C. albicans and C. parapsilosis. 
Six out of the fifteen strains exhibited inhibition against C. parapsilosis and all strains 
inhibited C. albicans. Zheng et al. (2000) reported that nine (52.9%) out of seventeen tested 
strains exhibited antifungal activity against fungi including C. albicans.  
Vikineswary et al. (1997) reported that eleven (33%) out of 33 actinomycetes 
strains isolated from a tropical mangrove ecosystem showed activity against all the test 
fungi including C. albicans. Okazaki and Okami (1976) reported that only two strains out 
of 37 antagonistic actinomycetes exhibited antifungal properties. This is also in agreement 
with the present study because the percentage of antifungal activity was smaller. Shiomi et 
al. (2005) reported that the antimycins (produced by Streptomyces sp. K01-0031) have also 
other biological properties such as antifungal activity, inhibition of enzymatic activity as 
well as the ability to induce the death of cancer cells.  
Vikineswary et al. (1997) reported that 11 strains (33%) out of 33 strains of 
actinomycetes isolated from marine environment showed antifungal activity by cross-plug 
method. The authors also reported that ten out of eleven actinomycetes strains exhibited 
antifungal activity against C. albicans by shake flasks studies. This is again in agreement 
with the results obtained in the present study because antifungal activity was only recorded 
against fungi including C. albicans only in secondary screening. The authors reported that 
only the culture supernatant was tested for bioactivity. The bioactive substance could be 
membrane-bound or intracellular. However, in the present study, all the culture mixtures 
were tested for bioactivity.  
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4.2 Antagonistic activity of different colour groups of selected Streptomyces spp. 
against test microorganisms 
Table 4.6 shows the antagonistic activity of different colour groups of selected 
Streptomyces spp. against test microorganisms in primary and secondary screening. Figure 
4.1 a – h shows the antagonistic activity of different colour groups of selected Streptomyces 
spp. against test microorganisms in primary screening.  
 
Table 4.6: Antagonistic activity of different colour groups of selected Streptomyces 
spp. against test microorganisms in primary and secondary screening 
Colour 
groups  Strains 
Test microorganismsa 
Gram-positive bacteria Gram-negative bacteria Fungi  
EF SA BS PS PA CP CA 
1ob 2oc 1o 2o 1o 2o 1o 2o 1o 2o 1o 2o 1o 2o 
Grey T3 + + + + - + - + - - - - - - T4 - + - + - + - + - - - + - + 
White/Red  
T9 + + + + + + + + + + - + - - 
T12 + + + + + + + + + + - + - - 
T13 + + + + + + + + + - - + - - 
T15 + + + + + + + + + - - + - + 
T52 + + + + + + + + + + - - - - 
White/Brown  
T6 + + - + - + - + + - - - - - 
T16 - + - + - + - + - - - + - + 
T20 - + - + - + - + - - - - - - 
T53 + + - + + + + + + + - + - + 
a Test microorganisms: SA: S.aureus; BS: B.subtilis; EF: E.faecalis; PS: P.shigelloides; PA: P.aeruginosa; 
CP: C.parapsilosis and CA: C.albicans; b 10: Primary screening: Cross streak method was applied on ISP4 for 
T3 and T4 and SA for the remaining strains. The plates were incubated for 48 hours at 37±2oC; c 20: 
Secondary screening: Paper disc method was applied on NA for test bacteria and on SDA for test fungi. The 
discs were loaded with 15µl of crude extracts and the plates were incubated for 24 hours at 37±2oC;              
+: Inhibition; -: No inhibition    
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a) Strain T9     b) Strain T12        c) Strain T13 
        
 
 
 
 
 
 
 
 
d) Strain T15       e) Strain T52      f) Strain T53 
          
 
 
 
 
 
 
 
 
g) Control       h) Control 
 
         
          
 
 
 
 
 
Figure 4.1: Antagonistic activity of different colour groups of selected Streptomyces sp 
strains in primary screening against; 1) E. faecalis; 2) S. aureus; 3) P. 
shigelloides; 4) B. subtilis; 5) P. aeruginosa on ISP4 for strains T3 and T4 
and SA for the remaining strains after 48 hours incubation at 37±2oC 
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All strains of grey, white/red and white/brown colour groups inhibited the growth of 
all Gram-positive bacteria in secondary screening. Inhibition of the growth of P. 
shigelloides by all strains was also recorded in secondary screening. All strains of different 
colour groups did not inhibit the growth of test fungi in primary screening. 
Table 4.7 shows the inhibition zones (mm) of different colour groups of selected 
Streptomyces spp. against test microorganisms in secondary screening. The degree of 
inhibition zones was grouped into weak (<10mm), moderate (10-15mm) and good 
(>15mm). Figure 4.2 a – l shows the antagonistic activity of different colour groups of 
selected Streptomyces spp. against test bacteria in secondary screening. The following 
analyses the anatagonistic activity of different colour groups of selected Streptomyces spp. 
against test microorganisms in primary and secondary screening.  
 
Grey colour group  
 The two strains in this colour group, strains T3 and T4 exhibited poor antagonistic 
activity against test microorganisms in primary screening (Table 4.6). The antagonistic 
activity was only recorded against E. faecalis and S. aureus. The two test microorganisms 
were inhibited by strain T3.  
 In secondary screening, the antagonistic activity was more prominent against Gram-
positive bacteria compared to Gram-negative bacteria. All the two strains inhibited the 
growth of all Gram-positive bacteria. Strains T3 and T4 inhibited the growth of only one 
test Gram-negative bacteria which was P. shigelloides. Antifungal activity was only 
recorded against C. parapsilosis and C. albicans. The test fungi were inhibited by strain T4. 
E. faecalis, S. aureus, B. subtilis and P. shigelloides were the most susceptible test 
microorganisms in this screening. The microorganisms were inhibited by all strains of grey 
colour group.  
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Table 4.7: Inhibition zones (mm) of selected Streptomyces spp. against test 
microorganisms in secondary screening on NA for test bacteria and on 
SDA for test fungi for 24 hours at 37±2oC 
C
ol
ou
r 
gr
ou
ps
 
St
ra
in
s Gram-positive bacteria Gram-negative bacteria Fungi 
Ef Sa Bs  Ps Pa Cp Ca 
G
re
y 
 T3 
1.7±1.2 
a 
2.3±1.5 
a 
4.0±3.0 
a 
4.7±0.6 
a 
- - - 
T4 
6.0±1.0 
ab 
5.3±2.3 
ab 
4.0±1.0 
a 
2.7±1.5 
ab 
- 
6.3±2.5 
b 
5.3±2.9 
ab 
W
hi
te
/re
d 
T9 
4.7±3.2 
ab 
6.3±2.1 
b 
1.7±1.2 
a 
6.0±1.0 
b 
2.5±0.7 
a 
1.7±1.2 
a 
- 
T12 
6.3±2.5 
b 
3.7±1.5 
ab 
5.0±1.7 
ab 
5.0±2.6 
ab 
5.0±4.2 
ab 
2.3±1.2 
a 
- 
T13 
2.0±1.0 
a 
4.7±1.5 
a 
4.0±2.0 
a 
12.0±1.0 
b 
- 
2.0±1.7 
a 
- 
T15 
7.7±2.1 
a 
6.3±2.1 
a 
12.0±1.7 
b 
16.3±0.6 
c 
- 
5.0±2.0 
a 
5.7±1.5 
a 
T52 
9.3±1.5 
a 
8.3±2.1 
a 
8.3±0.6 
a 
8.3±0.6 
a 
9.0±1.4 
a 
- - 
W
hi
te
/b
ro
w
n 
 
T6 
1.3±0.6 
a 
2.3±2.1 
b 
1.3±0.6 
a 
4.0±1.0 
b 
- - - 
T16 
6.3±4.7 
ab 
5.0±2.0 
ab 
9.3±1.5 
b 
15.7±1.5 
c 
- 
4.7±1.2 
a 
5.0±2.0 
ab 
T20 
8.3±1.5 
b 
8.0±2.6 
b 
8.0±1.0 
b 
1.3±0.6 
a 
- - - 
T53 
16.0±2.0 
c 
14.0±0 
bc 
13.7±0.6 
bc 
12.0±1.7 
bc 
13.0±1.4 
b 
5.3±2.5 
a 
 
6.7±0.6 
a 
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Table 4.7, Continuation  
 
Streptomycin, 10µg (S10) 13 16 14 14 15 - - 
Novobiocin, 5µg (NB5) 15 13 15 18 16 - - 
Nystatin, 100µg (MY100) - - - - - 28 27 
Methanol 10.0±1.0 
10.3± 
1.5 
11.3± 
0.6 
9.0± 
1.0 
12.5± 
0.7 
11.7± 
0.6 
13.3± 
0.6 
Values expressed are mean and standard deviation of triplicate measurements. Means with different letters in 
a same row are significantly different  (p<0.05); Ef:E faecalis; Sa:S. aureus; Bs:B. subtilis; Ps:P. shigelloides; 
Pa:P.aeruginosa; Cp:C. parapsilosis; Ca:C. albicans 
 
 
a)               b) Control plate for E. faecalis 
       
 
          C2          C3 
    C1 
   
    Inhibition zone produced  
    by T53 against E.faecalis 
 
 
c)               d) Control plate for S. aureus 
       
          C2         C3 
     
   C1                                 
                 Inhibition zone produced  
                                        by T53 against S.aureus 
 
 
e)               f)  
        Inhibition zone produced by  
     T16 against P.shigelloides 
                     C1                                 C1 
 
    Inhibition zone produced  by  
       T15 against P.shigelloides 
                  Inhibition zone produced  
by strain T53 against P.shigelloides  
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g) Control plate for P.shigelloides                     h) 
     
        C2 C3           Inhibition zone produced       
         by strain T15 against           C1 
B.subtilis 
 
 
 
i)               j) Control plate for B.subtilis 
       
   C2      C3             
 C1                    
                Inhibition zone produced  
                      by strain T53 against B.subtilis 
      
 
k)                         l) Control plate for P.aeruginosa  
       
  C2      C3 
    C1       
                Inhibition zone produced by 
                            strain T53 against 
               P.aeruginosa 
 
Figure 4.2: Antagonistic activity of selected Streptomyces sp strains in secondary 
screening against test bacteria after 24 hours incubation at 37±2oC. 
Negative control: C1 (Methanol); Positive control: C2 (Streptomycin, 10µg) and C3 
(Novobiocin, 5µg). 
 
Strains T3 and T4 exhibited weak antagonistic activity (<10mm) against the test 
microorganisms (Table 4.7). The degree of inhibition zones of strain T3 against test 
microorganisms followed the order of P. shigelloides (4.7±0.6mm) > B. subtilis 
(4.0±3.0mm) > S. aureus (2.3±1.5mm) > E. faecalis (1.7±1.2mm) (Table 4.8). However, 
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there were no significant differences (p>0.05) (Appendix B, Table 1) of the inhibition 
zones between the four test microorganisms.  
The inhibition zones of strain T4 against test microorganisms followed the order E. 
faecalis (6.0±1.0mm) > C. parapsilosis (6.3±2.5mm) > S. aureus (5.3±2.3mm) > B. subtilis 
(4.0±1.0mm) > C. albicans (5.3±2.9mm) > P. shigelloides (2.7± 1.5mm) (Table 4.8). 
However, there were no significant differences (p>0.05) (Appendix B, Table 2). Strain T4 
was the most active strain. The strain exhibited antagonistic activity against four test 
bacteria and all test fungi.  
  
White/Red colour group  
Strains of white/red colour group were active in both primary and secondary 
screening (Table 4.6). All the five strains showed good antagonistic activity against test 
bacteria in primary screening. All strains inhibited the growth of all test bacteria. The 
antibacterial activity was more prominent than antifungal activity in primary screening. No 
antifungal activity was recorded in this screening. E. faecalis, S. aureus, B. subtilis, P. 
shigelloides and P. aeruginosa were the most susceptible test bacteria in this screening. The 
growth of the bacteria was inhibited by all strains of white/red colour group. 
In secondary screening, all the five strains exhibited good antagonistic activity 
against all Gram-positive bacteria. All strains also exhibited antagonistic activity against P. 
shigelloides. However, only three strains inhibited the growth of P. aeruginosa. The strains 
were T9, T12 and T52. Four strains exhibited antagonistic activity against C. parapsilosis. 
The strains were T9, T12, T13 and T15. The growth of C. albicans was inhibited by only 
one strain which was T15. E. faecalis, S. aureus, B. subtilis and P. shigelloides were the 
most susceptible test bacteria in this screening. All strains exhibited antagonistic activity 
against the test bacteria.  
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Strain T15 showed good antagonistic activity (>15mm) against P. shigelloides 
(16.3±0.6mm) (Table 4.7). This strain also showed moderate antagonistic activity (10-
15mm) against B. subtilis (12.0±1.7mm) and weak antagonistic activity (<10mm) against 
other test microorganisms. The inhibition zones of strain T15 against test microorganisms 
followed the order P. shigelloides (16.3±0.6mm) > B. subtilis (12.0±1.7mm) > E. faecalis 
(7.7±2.1mm) > S. aureus (6.3±2.1mm) > C. albicans (5.7±1.5mm) > C. parapsilosis (5.0± 
2.0). The inhibition zones of strain T15 against P. shigelloides was significantly higher than 
E. faecalis, S. aureus, B. subtilis, C. parapsilosis and C. albicans, as well as the inhibition 
zones of strain T15 against B. subtilis which was significantly higher than E. faecalis, S. 
aureus, C. parapsilosis and C. albicans (p=0.05) (Appendix B, Table 10 and 11).   
Strain T13 showed moderate antagonistic activity (10-15mm) against P. 
shigelloides (12.0±1.0mm) and weak antagonistic activity (<10mm) against other test 
microorganisms. The inhibition zones of strain T13 against test microorganisms followed 
the order P. shigelloides (12.0±1.0mm) > S. aureus (4.7±1.5mm) > B. subtilis 
(4.0±2.0mm) > E. faecalis (2.0±1.0mm) > C. parapsilosis (2.0± 1.7) (Table 4.8). The 
inhibition zones of strain T13 against P. shigelloides was significantly higher than E. 
faecalis, S. aureus, B. subtilis and C. parapsilosis (p<0.05) (Appendix B, Table 8 and 9). 
  Strain T9 showed weak antagonistic activity (<10mm) against the test 
microorganisms. The inhibition zones of strain T9 against test microorganisms followed the 
order P. shigelloides (6.0±1.0mm) > S. aureus (6.3±2.1mm) > P. aeruginosa (2.5±0.7mm) 
> E. faecalis (4.7±3.2mm) > B. subtilis (1.7±1.2mm) > C. parapsilosis (1.7±1.2mm). The 
inhibition zones of strain T9 against S. aureus and P. shigelloides were significantly higher 
than B. subtilis, P. aeruginosa and C. parapsilosis (p<0.05) (Appendix B, Table 5 and 6).  
 Strain T12 also showed weak antagonistic activity (<10mm) against the test 
microorganisms. The inhibition zones of strain T12 against test microorganisms followed 
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the order E. faecalis (6.3±2.5mm) > B. subtilis (5.0±1.7mm) > P. shigelloides 
(5.0±2.6mm) > S. aureus (3.7±1.5mm) > C. parapsilosis (2.3± 1.2mm) > P. aeruginosa 
(5.0±4.2mm). However, there were no significant differences (p>0.05) (Appendix B, Table 
7).  
 Strain T52 showed weak antagonistic activity (<10mm) against the test 
microorganisms.  The inhibition zones of strain T52 against test microorganisms followed 
the order E. faecalis (9.3±1.5mm) > B. subtilis (8.3±0.6mm) > P. shigelloides 
(8.3±0.6mm) > P. aeruginosa (9.0±1.4mm) > S. aureus (8.3±2.1mm). There were no 
significant differences between the inhibition zones of strain T52 against all test 
microorganisms (p>0.05) (Appendix B, Table 16). 
 
White/Brown colour group 
 Strains of white/brown colour group exhibited poor antagonistic activity in primary 
screening (Table 4.6). Strain T6 only showed antagonistic activity against E. faecalis and P. 
aeruginosa in primary screening. Strain T53 inhibited the growth of all test bacteria except 
S. aureus. No antifungal activity was recorded in this screening. 
 In secondary screening, antagonistic activity against Gram-positive bacteria was 
more prominent compared to Gram-negative bacteria. All the four strains of white/brown 
colour group exhibited antagonistic activity against all Gram-positive bacteria. All strains 
also showed antagonistic activity against P. shigelloides. The growth of P. aeruginosa was 
only inhibited by strain T53. Only two strains exhibited antagonistic activity against C. 
parapsilosis and C. albicans. They were strains T16 and T53. E. faecalis, S. aureus, B. 
subtilis and P. shigelloides were the most susceptible test microorganisms in this screening. 
All strains of white/brown colour group exhibited antagonistic activity against the test 
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bacteria. Strain T53 was the most active strain. The strain showed antagonistic activity 
against all test microorganisms in secondary screening.  
 Strain T53 exhibited good antagonistic activity (>15mm) against E. faecalis 
(16.±2.0mm). The strain also showed moderate antagonistic activity (10-15mm) against S. 
aureus (14.0±0.0mm), B. subtilis (13.7±0.6mm), P. shigelloides (12.0±1.7mm) and P. 
aeruginosa (13.0±1.4mm) and weak antagonistic activity (<10mm) against the remaining 
strains (Table 4.7). The inhibition zones of strain T53 against test microorganisms followed 
the order E. faecalis (16.0±2.0mm) > S. aureus (14.0mm)> B. subtilis (13.7±0.6mm) > P. 
aeruginosa (13.0±1.4mm) > P. shigelloides (12.0±1.7mm) > C. albicans (6.7±0.6mm) > 
C. parapsilosis (5.3±2.5mm). There were significant differences between the inhibition 
zones of strain T53 against E. faecalis with P. shigelloides, P. aeruginosa, C. parapsilosis 
and C. albicans, as well as the inhibition zones between S. aureus, P. shigelloides, B. 
subtilis and P. aeruginosa which were significantly higher than C. parapsilosis and C. 
albicans (p=0.05) (Appendix B, Table 17 and 18). 
 Strain T6 exhibited weak antagonistic (<10mm) against the test microorganisms. 
The inhibition zones of strain T6 against test microorganisms followed the order P. 
shigelloides (4.0±1.0mm) > E. faecalis (1.3±0.6mm) > B. subtilis (1.3±0.6mm) > S. aureus 
(2.3±2.1mm). The inhibition zones of strain T6 against P. shigelloides was significantly 
higher than E. faecalis and against B. subtilis as well as the inhibition zone o f B. subtilis 
which was significantly higher than S. aureus (p<0.05) (Appendix B, Table 3 and 4). 
 Strain T16 showed good antagonistic activity (>15mm) against P. shigelloides 
(15.7±1.5mm) and weak antagonistic activity (<10mm) against the remaining test 
microorganisms. The inhibition zones of strain T16 against test microorganisms followed 
the order P. shigelloides (15.7±1.5mm) > B. subtilis (9.3±1.5mm) > C. parapsilosis (4.7± 
1.2mm) > S. aureus (5.0±2.0mm) > C. albicans (5.0±2.0mm) > E. faecalis (6.3±4.7mm). 
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The inhibition zones of strain T16 against P. shigelloides was significantly higher than E. 
faecalis, S. aureus, B. subtilis, C. parapsilosis and C. albicans, as well as the inhibition 
zones of strain T16 against B. subtilis which was significantly higher than C. parapsilosis 
(p<0.05) (Appendix B, Table 12 and 13). 
 Strain T20 exhibited weak antagonistic activity (<10mm) against the test 
microorganisms. The inhibition zones of strain T20 against test microorganisms followed 
the order B. subtilis (8.0±1.0mm) > E. faecalis (8.3±1.5mm) > S. aurues (8.0±2.6mm) > P. 
shigelloides (1.3±0.6mm). The inhibition zones of strain T20 against E. faecalis, S. aureus 
and B. subtilis was significantly higher than P. shigelloides (p<0.05) (Appendix B, Table 
14 and 15). 
 The results obtained in present study showed that majority of active strains 
exhibited weak antagonistic activity against test microorganisms. Shomura et al. (1979) 
reported that the failure of antibiotic productivity during Streptomyces spp. growth in 
submerged culture correlated with their mycelial morphology. In agar cultures, the 
mycelium of Streptomyces spp. was in filamentous form, but once cultivated in submerged 
culture they formed fragments. This resulted in reduced potential of antibiotics production 
by Streptomyces spp. 
In the present study, majority of strains of grey, white/red and white/brown colour 
groups exhibited prominent antagonistic activity against Gram-positive bacteria. Majority 
of strains of white/red colour group, strain T3 of grey and two strains of white/brown 
colour groups were active against both bacteria and fungi. This might be due to the action 
of more than one antibiotic with different targets (Gonzales et al., 1999). The broad 
spectrum of the strains might also be due to possible presence of a new antimicrobial 
substance which was able to cross both bacterial and fungal cell walls (Tsvetanova and 
Price, 2001) 
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Kavithambigai (2006) reported that antimicrobial activity of active strains in grey 
colour group was prominent in primary screening. Active strains inhibited the growth of B. 
subtilis and S. aureus in both primary and secondary screening. Majority of active strains 
showed moderate antibiosis (inhibition between 11-20mm) against B. subtilis and S. aureus 
and one strain showed good antibiosis (inhibition more than 20mm) against B. subtilis. This 
is however not in agreement with the results obtained in the present study because strains in 
grey colour group were more prominent in secondary screening than in primary screening. 
The strains also showed weak inhibition zone against the test bacteria. This might explain 
the difference in bioactive substances in actinomycetes from marine ecosystem with root 
samples.   
 In this study, strain T53 of white/brown colour group was the most active strain. 
The strain inhibited the growth of all test microorganisms. Strain T53 produced inhibition 
zone of 13.0±1.4mm against P. aeruginosa, 14.0±0.0mm against S. aureus and 13.7±0.6mm 
against B. subtilis. Selvin et al. (2004) reported that the extracellular proteins of 
Streptomyces strain BTL7 isolated from marine sponge Dendrilla nigra produced inhibition 
zone of 21mm against P. aeruginosa, 16mm against S. aureus and 15mm for B. subtilis. 
This is quite similar with the result obtained in the present study. Tan et al. (2004) reported 
that comparable inhibition relative to 10µg streptomycin standard was shown by majority 
of the strains against S. aureus, B subtilis and P. aeruginosa. Bioactivity of all extracts 
tested against P. aeruginosa was the weakest, followed by B. subtilis and strongest against 
S. aureus. This is however not comparable with the present study because active strains 
produced different degree of inhibition zone against the test bacteria.  
 Tan et al. (2004) reported that comparable or better inhibition compared to nystatin 
standard (15mm) was observed against C. albicans. Strains X13, X46 and X60 produced 
inhibition zone bigger by 18% each to nystatin standard. Strain Z250 produced inhibition 
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zone bigger by 29% to nystatin standard. Sacramento et al. (2004) reported that the crude 
supernatants of Streptomyces sp. strain 606 showed zones of wide inhibition against yeast 
(C. albicans, 23mm). This is however not in agreement with the result obtained in present 
study. The test marine actinomycetes produced weak inhibition zone against the test fungi.   
This study showed that the inhibiton produced by active strains against the test fungi was 
not comparable to nystatin standard. This might suggest that the actinomycetes strains in 
this study did not have antifungal substance to inhibit the growth of the test fungi. 
 Devi et al. (2006) reported that out of three selected and identified actinomycetes, 
Streptomyces sp. showed significant antimicrobial activity against human pathogens. The 
highest zone of inhibition of 57 mm antimicrobial activity was showed by Streptomyces sp. 
against P. aeruginosa. Marine Streptomyces sp. exhibited the highest antibacterial activity 
against P. aeruginosa followed by S. aurues. This is not in agreement with the present 
result obtained in the present study. The highest inhibition zone was showed against P. 
shigelloides, followed by E. faecalis. This might suggest that marine actinomycetes have 
different antibacterial substances.    
 Sacramento et al. (2004) reported that P. aeruginosa was resistant to crude 
supernatant, extracts and fractions of Streptomyces sp. strain 606 isolated from a Brazilian 
tropical forest soil. This is quite comparable to the result obtained in present study because 
only a few strains inhibited the growth the test bacteria.  
The search for novel metabolites especially from actinomycetes requires a large 
number ofisolates (over thousands) in order to discover a novel compound of 
pharmaceutical interest. The search will be more promising if diverse actinomycetes are 
sampled and screened (Lo et al., 2002).  
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4.3 Media optimization  
Figure 4.3 a – c shows the antagonistic activity of crude extracts of strain T53 
against E. faecalis in ISP2 medium. Table 4.8 shows the inhibition zones of crude extracts 
of strain T53 against E. faecalis in agitation and static fermentation conditions using three 
different media. Inhibition zones of crude extracts of strain T53 against E. faecalis was only 
observed in SA and ISP2 media in agitation and static fermentation condition. In SA 
medium, in agitation fermentation condition, the inhibition zone was recorded in day 9 and 
day 12. In static fermentation condition, the inhibition zone was only observed in day 9. In 
ISP2 medium, the inhibition zone was only recorded in day 3, day 6, day 9 and day 12 in 
agitation fermentation condition. Plate 4.3 a – c shows the antagonistic activity of crude 
extracts of strain T53 against E. faecalis in ISP2 medium. Table 4.9 shows the pH value of 
crude extracts of submerged cultures fermentation of T53 in agitation and static 
fermentation conditions. 
 
SA medium  
In SA medium, antibacterial activity could be observed in both agitation and static 
fermentation conditions (Table 4.8). In agitation fermentation, the antibacterial activity was 
recorded in day 9 and day 12. Antibacterial activity in static fermentation condition was 
only observed in day 9.     
The inhibition zones of strain T53 against E. faecalis in SA medium followed the 
order of day 12 (Agitation) (10.3±1.5mm) > day 9 (Agitation) (6.0±5.2mm) > day 9 (Static) 
(8.7±0.6mm) (Table 4.8). However, there were no significant differences (p>0.05) 
(Appendix B, Table 19) of the inhibition zones between the three different days.  
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There were also no significant differences in the pH value pH value of crude 
extracts of submerged cultures fermentation of T53 in agitation and static fermentation 
conditions (p>0.05) (Appendix B, Table 21).  
 
a)         b) 
     SH  ST    
          D3        D3 
  
         C1             
   D6       D6        
   D9       D9 
   
 
         D12            D12 
        
 
 
 
c) 
        
 
 
  C2          C3 
 
 
 
 
 
 
 
 
 
Figure 4.3: Antagonistic activity of crude extracts of T53 against E. faecalis in ISP2    
medium after 24 hours incubation at 37±2oC. Negative control: C1 
(Methanol); Positive control: C2 (Streptomycin, 10µg) and C3 
(Novobiocin, 5µg); SH: Shaking fermentation condition; ST: Static 
fermentation condition 
 
54 
 
Table 4.8: Inhibition zones (mm) of crude extracts of submerged cultures 
fermentation of strain T53 against E. faecalis in agitation and static 
fermentation conditions on SA, ISP2 and ISP4 for 24 hours 37±2oC 
 Submerged cultures fermentation conditions 
Agitation  Static 
Days 
 
Media 
3 6 9 12 3 6 9 12 
SA - - 9.3±0.6a 10.3±1.5a - - 8.7±0.6a - 
ISP2 8.7±1.2a 8.3±0.6a 10.7±1.2b 8.7±1.2a - - - - 
ISP4 - - - - - - - - 
Values expressed are mean and standard deviation of triplicate measurements. Means with different letters in 
a same row are significantly different (p<0.05). 
 
 
ISP2 medium  
 In ISP2 medium, the antibacterial activity was only observed in agitation 
fermentation condition (Table 4.8). In agitation fermentation condition, the antibacterial 
activity was recorded in days 3, 6, 9 and 12. No antibacterial activity was recorded in static 
fermentation condition.     
The inhibition zones of crude extracts of strain T53 against E. faecalis in agitation 
fermentation condition followed the order of Day 9 (10.7±1.2) > Day 6 (8.3±0.6) > Day 3 
(8.7±1.2) > Day 12 (8.7±1.2). However, there were no significant differences (p>0.05) 
(Appendix B, Table 20). 
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Table 4.9: pH value of crude extracts of submerged cultures fermentation of strain 
T53 in agitation and static fermentation conditions on SA, I2 and I4 for 
24 hours 37±2oC 
 
Submerged cultures fermentation conditions 
Agitation  Static 
   Days 
Media 
3 6 9 12 3 6 9 12 
SA 
7.10±0.
51ab 
7.86±
0.18c 
7.12± 
0.26abc 
7.18± 
0.05abc 
6.67± 
0.38a 
6.99± 
0.39ab 
7.18± 
0.89abc 
7.55± 
0.24 bc 
ISP2 
6.80± 
0.20abc 
6.28±
0.25a 
6.43± 
0.20a 
6.57± 
0.03ab 
6.78± 
0.06ab 
6.82± 
0.53abc 
7.06± 
0.27bc 
7.39± 
0.69c 
ISP4 
7.35± 
0.24c 
6.14±
0.03ab 
6.08± 
0.40ab 
6.87± 
0.56bc 
6.64± 
0.66abc 
6.69± 
0.62abc 
5.98± 
0.19a 
6.50± 
0.69ab 
Values expressed are mean and standard deviation of triplicate measurements. Means with different letters in 
a same row are significantly different (p<0.05). 
 
 
The pH value (Table 4.9) shows that there were significant differences between the 
pH value of submerged cultures of strain T53 in day 6 (Agitation) (6.28±0.25) with day 9 
(Static) (7.06±0.27) and day 12 (Static) (7.39±0.69), day 9 (Agitation) (6.43±0.20) with day 
9 (Static) (7.06±0.27) and day 12 (Static) (7.39±0.69) as well as day 12 (Static) (6.57±0.03)  
with day 12 (Agitation) (7.39±0.69) and day 3 (Static) (6.78±0.06) (p<0.05) (Appendix B, 
Table 22 and 23). 
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ISP4 medium     
In ISP4 medium, no antibacterial activity was recorded in both shaking and static 
fermentation condition (Table 4.8). The pH value (Table 4.9) shows that there were 
significant differences between day 3 (7.35±0.24) in shaking fermentation condition with 
day 6 (6.14±0.03) and day 9 (6.08±0.40) in shaking fermentation condition and day 9 
(5.98±0.19) and day 12 (6.50±0.69) in static fermentation condition as well as day 12 
(6.87±0.56) in shaking fermentation condition with day 9 (5.98±0.19) in static fermentation 
condition (p<0.05) (Appendix B, Table 24 and 25).  
 
From this study, ISP2 was the best medium for bioactive compound production 
compared to SA and ISP4 media. Shake flask fermentation was the best fermentation 
system compared to static fermentation.  
In media optimization, dimethyl sulfoxide (DMSO) was used as a solvent to 
dissolve the crude extracts. The usage of methanol in secondary screening (Chapter 3, 
Section 3.4, page 24 – 26) was replaced with DMSO because of its low toxicity. Vignes 
(2000) reported that DMSO has very low toxicity to humans and the environment, 
recyclable after most uses, presents in many foods and plays a significant role in nature’s 
Global Sulfur Cycle, highly polar and aprotic solvent. The low toxicity of the solvent 
ensured that the inhibition zone of the test pathogens by the actinomycetes strains was not 
affected. 
 The production of bioactive secondary metabolites by actinomycetes is influenced 
by a few factors. Srinivasan et al. (1991) reported that antibiotics productivity of strains is 
profoundly influenced by factors such as the composition of the nutrient medium, 
temperature and duration of incubation. Other than that, the production is also influenced 
by fermentation conditions.  
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Antibiotic production generally takes place after the growth reaches the stationary 
phase or has passed an optimum level. Bu’lock (1961) reported that the production of 
secondary metabolites classically exhibits a two-stage process, with a trophophase (or 
growth phase) and an idiophase (or production phase), usually when growth has slowed or 
stopped. In the idiophase, productivity depends on maintenance of sub-optimal (cryptic) 
growth through control of the concentrations of inorganic phosphate, NH4+, metal ions, 
nitrogen or oxygen (Srinivasan et al., 1991). 
The nutritional factors strongly influence the production of bioactive secondary 
metabolites. The factors include the levels of inorganic phosphorus, metal ions, organic 
nitrogen sources and metabolic carbon, and in several cases substrate precursors are also 
important for high titres of the desired antibiotics (Higashide, 1984). Pisano et al. (1992) 
reported that the nature of the fermentation medium directly influenced the elaboration of 
antimicrobial substances.  
Carbon sources are one of the most important factors that influence the production 
of bioactive secondary metabolites. Glucose is generally used in the fermentation as a 
preferred carbon source but catabolite repression is avoided by feeding glucose during the 
fermentation. In some cases, carbohydrates, such as lactose, or polysaccharides, such as 
starch, which are used more slowly, have been found to be better carbon sources for 
antibiotic production (Srinivasan et al., 1991). Tiwaril et al. (2008) reported that 
actinomycetes can use peptone as carbon source too. Addition of glucose as carbon source 
allows better growth, and up to 0.8% of peptone can be used along with glucose for growth 
assessment of actinomcyetes. Farid et al. (2000) reported that natamycin production by 
Streptomyces natalensis required glucose in the submerged culture medium with a 
concentration of 20g/l. Sujatha et al. (2005) reported that Streptomyces psammmoticus 
strain BT-408 isolated from the sediments of Bay of Bengal Ocean produced maximum 
58 
 
antibiotic in medium supplemented with glucose as a sole carbon source followed by 
fructose and glycerol. The increased in glucose level in the culture from 10 to 12.5 g/l led 
to 1.2 fold increase in antibiotic production. Mellouli et al. (2003) reported that the highest 
antibacterial activities were obtained when starch at 1% (w/v) was used as sole carbon 
source in the presence of traces of mineral oligoelements. In another study reported by 
Fguira et al. (2005) highest antimicrobial activities were obtained in Streptomyces spp. 
when glucose at 1% (w/v) was used as sole carbon source in the presence of magnesium. 
Other than carbon sources, nitrogen sources are also important in the production of 
bioactive secondary metabolites. Iwai and Omura (1982) reported that the use of slowly-
consumed antifungal medium carbon sources such as soluble starch and nitrogen sources 
such as peptone and yeast-extract have been reported to be effective in the production of 
various types of antibiotics by actinomycetes especially the streptomycetes. Marwick et al. 
(1999) reported that the nitrogen source is understood to regulate secondary metabolism. 
High nitrogen levels have been noted to repress idiophase production of antibiotics 
(Marwick et al., 1999). Tiwaril et al. (2008) reported that actinomycetes can use inorganic 
nitrogen (KNO3), however organic nitrogen enhanced growth. Farid et al. (2000) reported 
that among different nitrogen sources tested, only ammonium sulphate, sodium nitrate and 
beef extract were the suitable nitrogen sources in supporting the antibiotic production. 
Furthermore, the mixture of beef extract and yeast extract (8 g/l and 2 g/l, respectively) 
exhibited a synergistic effect in enhancing the natamycin production reaching about 1.5 g/l. 
Sujatha et al. (2005) the highest antibiotic production was obtained in culture of 
streptomycete strain BT-408 containing ammonium nitrate as nitrogen source, followed by 
cultures containing sodium nitrate, potassium nitrate and alanine. 
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More than that, ammonium is also an important factor that influences the production 
of bioactive secondary metabolites. Zhang et al. (1996) found ammonium to stimulate an 
antibiotic produced by Streptomyces grisiofuscus. Srinivasan et al. (1991) reported that 
ammonium ion often exert a negative effect on production of several antibiotics 
(cephamycin, clavulanic acid and streptomycin) and in commercial fermentations use of a 
slowly metabolized nitrogen source (releasing ammonia slowly), such as soymeal, partially 
overcomes this problem. 
Phosphate is also important for the production of bioactive secondary metabolites. 
However, Spizek and Tichy (1995) reported that phosphate, although essential for growth, 
can at certain concentrations suppress secondary metabolism, inhibiting, for example, 
phosphatases and oxygenases. Srinivasan et al. (1991) also reported that fermentative 
production of aminoglycoside antibiotics, tetracyclines, polyenes and cephalosporins are 
sensitive to the phosphate concentration in the fermentation medium. Farid et al. (2000) 
reported that the highest antibiotic production was obtained in a cultivation medium 
containing 0.05 g/l of potassium dihydrogen phosphate. Further increase in phosphate 
concentration resulted in a significant increase in biomass concomitant with lower 
antibiotic production. Sujatha et al. (2005) reported that K2HPO4 at a concentration of 1.2 
g/l gave maximum yield of antibiotic. The addition of 0.5 g/l of magnesium sulfate to the 
culture medium was optimal for antibiotic production.  
Ions might also be important to improve the production of bioactive secondary 
metabolites. VanPee (1996) reported that in terms of marine bacteria, the concentration of 
bromide ions would seem to be significant in some cases, probably because of the 
prevalence of bromide in halogenated marine antibiotics. However, the macrolide antibiotic 
productivity tended to decrease when metal ion deficient media were used and also when 
the inocula were incubated for long periods and at high temperatures (Higashide, 1984).  
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These might be the reasons that are in agreement with the results obtained in the 
present study where ISP2 were the best medium for the production of bioactive secondary 
metabolites. Further research should be done to study the compositions of the media.   
However, other than nutritional factors, the production of bioactive compounds is 
also influenced by fermentation conditions. Submerged fermentation is the most common 
submerged culture system that was used to produce bioactive secondary metabolites. 
Pelczar and Reid (1972) reported that submerged cultures are widely used to produce many 
secondary metabolites because they allow filamentous fungi and bacteria to produce freely 
suspended mycelia and pellets, essential for secondary metabolite production. 
Agitation fermentation condition is also the most common submerged culture 
system that was used to produce bioactive secondary metabolites. Submerged culture 
fermentations require a stirred nutrient medium, and in the case aerobic microorganisms, a 
supply of oxygen (Duetz and Witholt, 2004). In small-scale fermentation, shake flasks are 
usually used. Standard Erlenmeyer flasks is one of the most common types used for small 
scale microbial fermentations because they are readily available, their conical shape allows 
vigorous shaking without spillages, the small opening limits evaporation so slow-growing 
strains can be cultivated without excess moisture loss and the relatively large surface at the 
bottom allows a high surface-to-volume ratio (Duetz and Witholt, 2004). This is in 
agreement with the results obtained in the present study where antibacterial activity of 
selected actinomycetes against test bacteria were recorded in shaking fermentation 
conditions. Sacramento et al. (2004) reported that after two weeks incubation under shaking 
(agitation) conditions, the supernatants of Streptomyces sp. strain 606 showed the largest 
inhibition zones against pathogenic microorganisms.  
Other than that, incubation temperature is also an important factor that influences 
the production of bioactive secondary metabolites. Sujatha et al. (2005) reported that the 
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increase of the incubation temperature from 20 to 30oC increased the growth of the cells of 
streptomycete strain BT-408 by 3-fold. The production of the antibiotic had also increased 
by 4.7-fold. Ouhdouch et al. (2001) reported that Streptomyces spp. usually produced 
antibiotics at temperatures near 27oC. Iwai and Omura (1992) reported that it would be 
interesting to use temperature shifts in antibiotic screening because the cultivation for 
antibiotic production was usually performed under constant temperature from the beginning 
until the end, but the adequate temperature for growth was not always the same as that for 
production.  
pH of the submerged cultures was also an important factor that influence the 
production of bioactive secondary metabolites. Sujatha et al. (2005) reported that the 
maximum antibiotic activity of streptomycete strain BT-408 was obtained at a pH of 7.2 the 
results also showed that an incubation time of 96 hours as optimal. Optimization of medium 
components and physical parameters (pH, temperature, time) allowed an improvement over 
182% in the concentration of antibiotic. Higashide (1984) reported that attainment of high 
antibiotic production required optimal concentration of the components in the fermentation 
medium, optimum pH and viscosity. Antibiotic production was optimum at 3% NaCl with 
slight decrease at 5%. Antibiotic production was comparable in the pH range of 7-9, 
whereas at pH10, there was no antibiotic production (Vasavada et al., 2006). Marwick et al. 
(1999) reported that the pH level of the growth medium has a marked effect on secondary 
metabolism production, with synthesis falling rapidly either side of an optimal level.  
  Tan et al. (2004) reported that the sensitivity of the antibacterial substances ex-situ 
towards light and temperature might influenced the antibacterial activity using crude 
extracts. The lower antibacterial activity might also due to naturally unstable antibacterial 
substances after prolonged storage or low amount of bioactive compound present in the 
crude extracts.  
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4.4 Conclusion  
· The antibacterial activity was higher in secondary screening compared to primary 
screening. The antifungal activity was only recorded in secondary screening with 
significantly higher percentage.   
 
· Gram-positive bacteria were more susceptible than Gram-negative bacteria. E. 
faecalis was the most susceptible Gram-positive bacteria. On the other hand, P. 
shigelloides was the most susceptible Gram-negative bacteria. The most susceptible 
fungi was C. parapsilosis.  
 
· Many of the selected Streptomyces spp. exhibited weak antagonistic activity against 
test pathogens. Strains T9, T12, T52 and T53 exhibited broad spectrum activity where 
they exhibited antibacterial activity against both Gram-positive and Gram-negative 
bacteria. Strains T4, T15, T16 and T53 exhibited antifungal activity against all test 
fungi.  
 
· Strains of grey, white/red and white brown colour groups exhibited antagonistic 
activity against all Gram-positive bacteria and against one Gram-negative test bacteria 
which was P. shigelloides.  
 
· Strain T53 of white/brown colour group exhibited antagonistic activity against all 
test bacteria and test fungi. This strain showed good inhibition against E. faecalis. 
Hence, it was concluded that strain T53 was the most active strain among the test 
microorganisms and E. faecalis was the most susceptible test bacteria.  
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· In media optimization, ISP2 was identified as the best medium for the production of 
bioactive secondary metabolites. Agitation fermentation condition was the best 
submerged culture fermentation condition for the production of bioactive secondary 
metabolites.  
 
· Further investigation should be done to study the composition as well as to identify 
the bioactive compounds produced by the selected marine actinomycetes. The 
composition of optimized media for the production of bioactive secondary metabolites 
should also be studied in further details.  
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APPENDIX A: MEDIA 
 
1 30% (v/v) GLYCEROL  
 Glycerol     360ml 
 Yeast extracts    1.2g 
 Glucose     4.5g 
 Casein     1.5g 
 Distilled water    840ml 
 
2 INORGANIC SALTS-STARCH AGAR (ISP4) 
 ISP4     18.5g  
 Sodium chloride (NaCl)  3g  
 Bacteriological agar   5g 
 Distilled water    1L 
 pH 7.2  
 
3 SPORULATION AGAR (SA) 
Yeast extract    4g (gly) 
CaCO3     1g 
Soluble starch    20g 
Glucose     15g (gly) 
K2HPO4    0.5g  
MgSO4.7H2O    0.5g 
Casein     5g (gly) 
Instant ocean 50%   17g 
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Agar     17g 
Distilled water    1L 
pH 7.0  
 
4 NUTRIENT AGAR (NA) 
 Nutrient agar powder    23g 
 Distilled water    1L 
 
5 SABAROUD DEXTROSE AGAR (SDA) 
 Sabaroud liquid broth powder  30g 
 Agar     20g    
 Distilled water    1L 
 
6 YEAST EXTRACT-MALT EXTRACT AGAR (ISP2) 
 Yeast extracts     2g 
 Malt extracts    5g 
 Glucose    2g 
 Sodium chloride (NaCl)  3g 
 Agar     20g 
 Distilled water    1L 
 pH     7.3 
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APPENDIX B: STATISTICAL TABLES  
Table 1: ANOVA: Inhibition zones of strain T3 against test microorganisms 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
17.6667 
26.0 
      43.6667      
3 
8  
11 
5.88889 
3.25 
 
1.81 0.2229* 
 
 *p > 0.05 
 
Table 2: ANOVA: Inhibition zones of strain T4 against test microorganisms 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
28.2778 
48.6667 
76.9444      
5 
12 
17 
5.65556 
4.05556 
 
1.39 
 
0.2939* 
 
*p > 0.05 
 
Table 3: ANOVA: Inhibition zones of strain T6 against test microorganisms 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
15.5833 
5.33333 
20.9167 
3 
8 
11 
5.19444 
0.666667 
 
7.79 0.0093* 
*p < 0.05 
 
Table 4: Multiple range tests: Inhibition zones of strain T6 against test 
microorganisms 
Contrast Difference +/-  Limits 
E. faecalis – S. aureus  
E. faecalis – P. shigelloides  
E. faecalis – B. subtilis  
*-1.66667              
*-2.66667                 
0.0             
1.53734 
1.53734 
1.53734  
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Table 4, Continuation  
Contrast Difference +/-  Limits 
S. aureus – P. shigelloides  
S. aureus – B. subtilis 
P. shigelloides – B. subtilis 
-1.0 
*1.66667                  
*2.66667               
1.53734 
1.53734 
1.53734            
* denotes a statistically significant difference. 
 
Table 5: ANOVA: Inhibition zones of strain T9 against test microorganisms 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
67.1667 
37.3333 
104.5 
5 
12 
17 
13.4333 
3.11111 
 
4.32 0.0176* 
*p < 0.05 
 
Table 6: Multiple range tests: Inhibition zones of strain T9 against test 
microorganisms 
Contrast Difference +/-  Limits 
E. faecalis – S. aureus 
E. faecalis – P. shigelloides 
E. faecalis – B. subtilis 
E. faecalis – P. aeruginosa 
E. faecalis – C. parapsilosis 
S. aureus – P. shigelloides  
S. aureus – B. subtilis 
S. aureus – P. aeruginosa  
S. aureus – C.parapsilosis 
P. shigelloides – B. subtilis 
P. shigelloides – P. aeruginosa 
P. shigelloides – C. parapsilosis 
1.66667              
4.33333              
3.0 
2.0               
3.0               
0.333333 
*4.66667               
 *3.66667 
*4.66667               
*4.33333 
*3.33333               
*4.33333                  
  3.13786                         
  3.13786                         
  3.13786                         
  3.13786                         
  3.13786                         
  3.13786                         
  3.13786                         
3.13786 
3.13786 
3.13786 
3.13786 
3.13786 
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Table 6, Continuation  
Contrast Difference +/-  Limits 
B. subtilis – P. aeruginosa 
B. subtilis – C. parapsilosis 
P. aeruginosa – C. parapsilosis 
-1.0              
0.0                   
1.0               
3.13786 
3.13786 
3.13786 
* denotes a statistically significant difference. 
 
Table 7: ANOVA: Inhibition zones of strain T12 against test microorganisms 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
29.6111       
58.6667     
88.2778      
5 
12 
17 
5.92222        
4.88889 
 
1.21 0.3614* 
*p > 0.05 
                           
Table 8: ANOVA: Inhibition zones of strain T13 against test microorganisms 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
204.267 
22.6667      
226.933 
4 
10 
14 
51.0667       
2.26667 
 
22.53       0.0001* 
*p < 0.05 
 
Table 9: Multiple range tests: Inhibition zones of strain T13 against test 
microorganisms 
Contrast Difference +/-  Limits 
E. faecalis – S. aureus 
E. faecalis – P. shigelloides 
E. faecalis – B. subtilis  
E. faecalis – C. parapsilosis 
-2.66667              
*-10.0                 
-2.0                  
0.0               
2.739            
2.739            
2.739        
2.739             
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Table 9, Continuation  
Contrast Difference +/-  Limits 
S. aureus – P. shigelloides  
S. aureus – B. subtilis 
S. aureus – C. parapsilosis 
P. shigelloides – B. subtilis 
P. shigelloides – C. parapsilosis 
B. subtilis – C. parapsilosis 
*-7.33333              
0.666667              
2.66667                  
*8.0                  
*10.0               
2.0               
2.739            
2.739            
2.739            
2.739         
2.739 
2.739            
 * denotes a statistically significant difference. 
 
Table 10: ANOVA: Inhibition zones of strain T15 against test microorganisms 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
295.833       
36.6667      
332.5      
5 
12 
17 
59.1667       
3.05556 
 
19.36       0.0000* 
*p = 0 
 
Table 11: Multiple range tests: Inhibition zones of strain T15 against test 
microorganisms 
Contrast Difference +/-  Limits 
E. faecalis – S. aureus 
E. faecalis – P. shigelloides 
E. faecalis – B. subtilis 
E. faecalis – C. parapsilosis 
E. faecalis – C. albicans 
S. aureus – P. shigelloides 
S. aureus – B. subtilis  
S. aureus – C. parapsilosis 
S. aureus – C. albicans 
1.33333 
*-8.66667  
*-4.33333              
2.66667               
2.0                   
*-10.0                 
*-5.66667              
1.33333               
0.666667                 
3.10971            
3.10971            
3.10971            
3.10971            
3.10971            
3.10971            
3.10971      
3.10971            
3.10971                    
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Table 11, Continuation  
Contrast Difference +/-  Limits 
P. shigelloides – B. subtilis 
P. shigelloides – C. parapsilosis 
P. shigelloides – C. albicans 
B. subtilis – C. parapsilosis 
B. subtilis – C. albicans 
C. parapsilosis – C. albicans 
*4.33333              
*11.3333              
*10.6667              
*7.0     
*6.33333              
 -0.666667                         
3.10971            
3.10971            
3.10971            
3.10971  
3.10971            
3.10971            
* denotes a statistically significant difference. 
 
Table 12: ANOVA: Inhibition zones of strain T16 against test microorganisms 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
275.333       
72.6667      
348.0      
5 
12 
17 
55.0667        
6.05556 
 
9.09        0.0009* 
*p < 0.05 
 
Table 13: Multiple range tests: Inhibition zones of strain T16 against test 
microorganisms 
Contrast Difference +/-  Limits 
E. faecalis – S. aureus 
E. faecalis – P. shigelloides 
E. faecalis – B. subtilis 
E. faecalis – C. parapsilosis 
E. faecalis – C. albicans 
S. aureus – P. shigelloides 
S. aureus – B. subtilis 
S. aureus – C. parapsilosis 
S. aureus – C. albicans 
1.33333               
*-9.33333              
-3.0                  
1.66667               
1.33333               
*-10.6667              
-4.33333              
0.333333              
0.0                   
4.37776 
4.37776 
4.37776 
4.37776 
4.37776 
4.37776 
4.37776 
4.37776 
4.37776 
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Table 13, Continuation  
Contrast Difference +/-  Limits 
P. shigelloides – B. subtilis 
P. shigelloides – C. parapsilosis 
P. shigelloides – C. albicans  
B. subtilis – C. parapsilosis 
B. subtilis – C. albicans 
C. parapsilosis – C. albicans 
*6.33333              
*11.0 
*10.6667     
*4.66667            
4.33333               
-0.333333             
4.37776 
4.37776 
4.37776 
4.37776 
4.37776 
4.37776            
* denotes a statistically significant difference. 
 
Table 14: ANOVA: Inhibition zones of strain T20 against test microorganisms 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
103.583       
21.3333       
124.917      
3 
8 
11 
34.5278 
2.66667 
 
12.95       0.0019* 
*p < 0.05 
 
Table 15: Multiple range tests: Inhibition zones of strain T20 against test 
microorganisms 
Contrast Difference +/-  Limits 
E. faecalis – S. aureus 
E. faecalis – P. shigelloides 
E. faecalis – B. subtilis 
S. aureus – P. shigelloides 
S. aureus – B. subtilis 
P. shigelloides – B. subtilis 
0.333333          
*7.0             
0.333333              
*6.66667                  
0.0                   
*-6.66667                    
3.07468            
3.07468            
3.07468            
3.07468            
3.07468            
3.07468            
* denotes a statistically significant difference. 
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Table 16: ANOVA: Inhibition zones of strain T52 against test microorganisms 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
2.66667       
16.6667      
19.3333      
4     
10 
14 
0.666667        
1.66667 
 
0.40        0.8045* 
*p > 0.05 
 
Table 17: ANOVA: Inhibition zones of strain T53 against test microorganisms 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
280.571       
30.6667      
311.238      
6      
14 
20 
46.7619      
2.19048 
 
21.35       0.0000* 
*p = 0 
 
Table 18: Multiple range tests: Inhibition zones of strain T53 against test 
microorganisms 
Contrast Difference +/-  Limits 
E. faecalis – S. aureus 
E. faecalis – P. shigelloides 
E. faecalis – B. subtilis 
E. faecalis – P. aeruginosa  
E. faecalis – C. parapsilosis 
E. faecalis – C. albicans 
S. aureus – P. shigelloides 
S. aureus – B. subtilis 
S. aureus – P. aeruginosa 
S. aureus – C. parapsilosis 
S. aureus – C. albicans 
P. shigelloides – B. subtilis 
P. shigelloides – P. aeruginosa 
2.33333                
*4.0                   
2.33333               
*3.0   
*10.6667               
*9.33333               
1.66667                  
0.0              
0.666667 
 *8.33333               
*7.0  
-1.66667              
-1.0                                              
2.59184 
2.59184 
2.59184 
2.59184 
2.59184 
2.59184 
2.59184 
2.59184 
2.59184 
2.59184 
2.59184 
2.59184 
2.59184 
90 
 
Table 18, Continuation  
Contrast Difference +/-  Limits 
P. shigelloides – C. parapsilosis 
P. shigelloides – C. albicans 
B. subtilis – P. aeruginosa 
B. subtilis – C. parapsilosis  
B. subtilis – C. albicans 
P. aeruginosa – C. parapsilosis 
P. aeruginosa – C. albicans 
C. parapsilosis – C. albicans 
*6.66667 
*5.33333               
0.666667              
*8.33333               
*7.0                   
*7.66667   
*6.33333               
-1.33333                         
2.59184 
2.59184 
2.59184 
2.59184 
2.59184 
2.59184 
2.59184 
2.59184 
* denotes a statistically significant difference.  
 
Table 19: ANOVA: SA medium: Inhibition zones of strain T53 against E. faecalis  
(shaking vs static) 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
4.22222       
6.0      
10.2222      
2 
6 
8 
2.11111        
1.0 
 
2.11 
 
0.2022* 
*p > 0.05 
 
 
Table 20: ANOVA: ISP2 medium: Inhibition zones of strain T53 against E. faecalis 
(shaking vs static) 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
10.25       
8.66667      
18.9167      
3 
8 
11 
3.41667        
1.08333 
 
3.15        0.0862* 
*p > 0.05 
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Table 21: ANOVA: pH of submerged cultures of strain T53 in SA  
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
2.6896       
3.0422      
5.7318      
7     
16 
23 
0.384229        
0.190137 
 
2.02        0.1156* 
*p > 0.05 
 
Table 22: ANOVA: pH of submerged cultures of strain T53 in ISP2 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
2.58105       
1.93253      
4.51358      
7 
16 
23 
0.368721        
0.120783 
 
3.05        0.0306* 
*p < 0.05 
 
 
Table 23: Multiple range tests: pH of submerged cultures of strain T53 in ISP2 
Contrast Difference +/-  Limits 
Day 3 (shaking) – Day 6 (shaking) 
Day 3 (shaking) – Day 9 (shaking) 
Day 3 (shaking) – Day 12 (shaking) 
Day 3 (shaking) – Day 3 (static) 
Day 3 (shaking) – Day 6 (static) 
Day 3 (shaking) – Day  9 (static) 
Day 3 (shaking) – Day 12 (static) 
Day 6 (shaking) – Day 9 (shaking) 
Day 6 (shaking) – Day 12 (shaking) 
Day 6 (shaking) – Day 3 (static) 
Day 6 (shaking) – Day 6 (static) 
Day 6 (shaking) – Day 9 (static) 
Day 6 (shaking) – Day 12 (static)  
Day 9 (shaking) – Day 12 (shaking) 
0.523333             
0.373333             
0.23                 
0.0266667            
-0.0166667           
-0.253333 
-0.583333            
-0.15 
 -0.293333 
-0.496667   
-0.54                
*-0.776667            
*-1.10667             
-0.143333 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
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Table 23, Continuation 
Contrast Difference +/-  Limits 
 
Day 9 (shaking) – Day 3 (static) 
Day 9 (shaking) – Day 6 (static) 
Day 9 (shaking) – Day 9 (static) 
Day 9 (shaking) – Day 12 (static) 
Day 12 (shaking) – Day 3 (static) 
Day 12 (shaking) – Day 6 (static) 
Day 12 (shaking) – Day 9 (static) 
Day 12 (shaking) – Day 12 (static) 
Day 3 (static) – Day 6 (static) 
Day 3 (static) – Day 9 (static) 
Day 3 (static) – Day 12 (static) 
Day 6 (static) – Day 9 (static) 
Day 6 (static) – Day 12 (static) 
Day 9 (static) – Day 12 (static) 
-0.346667            
-0.39                
*-0.626667            
*-0.956667            
-0.203333            
     -0.246667            
-0.483333            
*-0.813333  
-0.0433333           
-0.28                
*-0.61                
-0.236667            
-0.566667            
-0.33       
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
0.601555 
* denotes a statistically significant difference. 
 
Table 24: ANOVA: pH of submerged cultures of strain T53 in ISP4 
Source Sum of Squares Df Mean Square F-Ratio P-Value 
Between groups 
Within groups             
Total 
4.4461       
3.7174          
8.1635      
7 
16 
23 
0.635157        
0.232337 
 
2.73        0.0454* 
*p < 0.05 
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 Table 25: Multiple range tests: pH of submerged cultures of strain T53 in ISP4 
   
Day 3 (shaking) – Day 6 (shaking) 
Day 3 (shaking) – Day 9 (shaking) 
Day 3 (shaking) – Day 12 (shaking) 
Day 3 (shaking) – Day 3 (static) 
Day 3 (shaking) – Day 6 (static) 
Day 3 (shaking) – Day  9 (static) 
Day 3 (shaking) – Day 12 (static) 
Day 6 (shaking) – Day 9 (shaking) 
Day 6 (shaking) – Day 12 (shaking) 
Day 6 (shaking) – Day 3 (static) 
Day 6 (shaking) – Day 6 (static) 
Day 6 (shaking) – Day 9 (static) 
Day 6 (shaking) – Day 12 (static)  
Day 9 (shaking) – Day 12 (shaking) 
Day 9 (shaking) – Day 3 (static) 
Day 9 (shaking) – Day 6 (static) 
Day 9 (shaking) – Day 9 (static) 
Day 9 (shaking) – Day 12 (static) 
Day 12 (shaking) – Day 3 (static) 
Day 12 (shaking) – Day 6 (static) 
Day 12 (shaking) – Day 9 (static) 
Day 12 (shaking) – Day 12 (static) 
Day 3 (static) – Day 6 (static) 
Day 3 (static) – Day 9 (static) 
Day 3 (static) – Day 12 (static)  
Day 6 (static) – Day 9 (static) 
Day 6 (static) – Day 12 (static) 
Day 9 (static) – Day 12 (static) 
*1.21                 
*1.26667              
0.483333             
0.706667             
0.663333             
*1.37333              
*0.853333             
0.0566667            
-0.726667            
-0.503333 
-0.546667            
0.163333             
-0.356667            
-0.783333            
-0.56                
-0.603333            
0.106667             
-0.413333            
0.223333             
0.18                 
*0.89                 
0.37                 
-0.0433333           
0.666667             
0.146667             
0.71                 
0.19                 
-0.52                
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
0.834318           
*denotes a statistically significant difference. 
 
 
